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Epicutaneous patch testing is still regarded as the best method of coming to a 
diagnosis of allergic contact dermatitis. A lot of effort has been put into 
standardization of materials and methods used in patch testing. Patch tests can be 
used to confirm a suspected allergic contact dermatitis and either to recommend 
avoidance of particular products/chemicals or to recommend alternative products in a 
particular patient.  
Many technical problems are encountered. E.g. which allergens/test batteries have to 
be tested and which concentrations in which vehicle? These problems can more or 
less be solved in most cases. In chapter 1 allergic contact dermatitis and the patch 
test procedure and its limitations are discussed.  
The patch test procedure should also meet the standards of evidence based 
medicine (EBM). EBM in diagnostics and screening comprises the assessment of the 
validity, the accuracy (importance), the relevance and potential harm of a diagnostic 
procedure in relation to its costs. If applied to diagnosis and screening EBM can be 
referred to as evidence based diagnosis (EBD). Diagnostic tests are used in 
medicine to come to a diagnosis. The validity of a test answers the question: do the 
test results inform us about the disease process? In case of the patch test: do 
positive results indicate contact sensitization and not another biological phenomenon 
e.g. skin irritation? 
The patch test must be accurate. Does the patch test procedure accurately 
discriminate between those who have and those who have not a contact 
sensitization? To answer this question we need to be informed about the sensitivity, 
specificity and predictive values of the patch test procedure. 
The sensitivity of a test shows the test’s ability to recognise all persons with the 
disease studied. The specificity of a test shows the number of real negatives in the 
group of all persons without the disease studied or, in other words, the chance that a 
healthy person has a negative test result. The predictive value of a positive test is the 
chance that a person with a positive test really has the disease or will develop it in 
time. The predictive value of a negative test is the chance that a person with a 
negative test does not have the disease and will not develop it. 
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 Disease No disease 
Positive A B  
Test 
Negative C D 
 
Sensitivity: A/A+C          Specificity: D/D+B          
Positive predictive value: A/A+B    Negative predictive value: D/C+D 
In the case of patch testing, sensitivity indicates the number of sensitized patients 
with a positive test and specificity the number of patients not sensitized to an allergen 
with a negative test for the specific allergen. In other words, the test should detect as 
much contact allergic persons as possible (high sensitivity). As much as possible 
patients with dermatitis that is not allergic in origin should have a negative patch test 
(high specificity). Irritant patch test reactions, which clinically cannot be distinguished 
from allergic ones, often pose problems for he who reads the tests. Moreover, the 
patch test reaction is not simply a positive or negative one, but a spectrum of 
clinically different reactions, categorized as 1+ to 3+. The common screening 
allergens used to patch test patients thought to have contact dermatitis are estimated 
to have a sensitivity of 70% and a specificity of 70%. Chapters 3 and 4 provides 
information on the accuracy of patch test results and the influence of the strength of 
the (positive) patch test reaction on the accuracy respectively.  
Although the concepts of sensitivity and specificity are needed to determine the 
accuracy, they are in themselves not very useful. The clinician is more interested in 
the odds that a person has the disease or not, and to what extent a diagnostic test 
can help to estimate the probability of disease after testing. For that purpose, we 
have delineated the concepts of likelihood ratio, pre-test and post-test odds and pre-
test and post-test probability (chapter 3).  
Patch testing is as much art as it is science; we all are influenced by our clinical 
experience as well as by the literature. Careful history taking combined with physical 
examination is extremely important in deciding whether or not to patch test and in 
deciding which materials should be tested in order to increase the predictive values 
of patch test results (chapter 3). 
What is the relevance of a positive patch test? Does the patch test results inform us 
about the current disease process or is it a remnant of past sensitization? 
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The true rate of clinically relevant hypersensitivity in positive patch test reactions 
remains for a great part unknown. To know that a patient has been exposed to a 
sensitizer is insufficient to conclude that the positive patch test is relevant. There is 
always the risk to over- or underestimate the relevance of positive patch test 
reactions. The relevance of the positive patch test reactions is not always easy to 
judge. For practical reasons it can be categorized as definite, probable or possible. A 
careful history taking, attention for the clinical picture and thorough follow-up are key 
actions to facilitate the interpretation of the clinical relevance of the epicutaneous 
patch test results. 
 
The problem is that one sensitizer causing the entire clinical picture of the dermatitis 
is rare. Mostly the cause is multifactorial, including irritant and constitutional 
influences. It is important to obtain sufficient information on the exposure to the 
suspected sensitizer, by questioning the patient’s own experience, analyzing data 
sheets on packages of used products, chemical analyses, etc. Patient’s own 
suspected products are often tested and in case of a positive patch test reaction to 
one of them, the ingredients must be analyzed. Repeated open application (ROAT’s) 
tests are generally carried out in a standardized manner, but sometimes the 
diagnostic value may increase when the test simulates ordinary use conditions. In 
chapters 4, 5 and 6 the relevance of positive patch test results is discussed in 
different clinical pictures. In some products the concentration of the sensitizer is too 
low to elicit a patch test reaction, but sufficient to cause dermatitis in daily life 
conditions with frequent exposures often on damaged skin. Often the substances 
giving rise to positive patch test results represent aggravating factors, but are not the 
cause of the primary dermatitis. This is especially true for reactions to medications, 
e.g. eardrops, used to treat a pre-existent skin disease, such as a chronic otitis 
externa (chapter 6). 
Just as a positive reaction does not always mean that the primary cause of the 
dermatitis has been found, so a negative reaction does not always mean that the 
dermatitis is not caused by contact allergic hypersensitivity. Standard series include 
only statistically common allergens; one must be constantly alert to the possibility of 
contact allergy to ingredients of products not present in standard series and rare, 
exotic or new sensitizers. 
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Finally, the test should be performed at proper indication. Does a potential benefit 
outweigh potential harm and the costs of the procedure in a specific patient? The 
ideal patch test should cause as few adverse reactions as possible. Many adverse 
reactions have been described, but in general the overall risk-benefit equation of 
patch testing is considered to be in favour of the benefit, if performed correctly and at 
proper indication. In chapter 2 an example is provided of potential harm, which can 
be inflicted to a patient by the patch test procedure and which can outweigh a 
potential benefit. 
In chapters 7.1, 7.2 and 7.3 case reports are provided, showing that good history 
taking, thorough clinical examination and evidence based patch testing and follow-up 
can help to come to a correct diagnosis. 
In summary, the purpose of this thesis is to enlighten the limitations and to come to 
recommendations to raise the value of patch testing. Data are presented which may 
be helpful in the implementation of EBD in patch testing. 
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Chapter 1 
 
General introduction on allergic contact dermatitis and patch testing. 
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Abstract 
Epicutaneous patch testing is still regarded as the best method of coming to a 
diagnosis of allergic contact dermatitis. The present patch test technique is the result 
of a continuous process of development and improvement since its first application in 
the late 19th century. During the last decades of the 20th century, a lot of effort has 
been put into standardization of materials and methods used in patch testing. Patch 
tests can be used to confirm a suspected allergic contact dermatitis and either to 
recommend avoidance of particular products or to recommend alternative products in 
a particular patient. The true rate of clinically relevant hypersensitivity in positive 
patch test reactions remains for a great part unknown. The ideal patch test should 
cause as few adverse reactions as possible, but many adverse reactions have been 
described, but it has to be noted that the overall risk-benefit equation of patch testing 
is in favour of the benefit, if performed correctly and at proper indication. A careful 
history taking and attention for the clinical picture are key actions to facilitate the 
interpretation of the clinical relevance of the epicutaneous patch test results. 
Key words 
allergy, contact dermatitis, patch test, relevance, review, technique 
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Introduction 
Allergic contact dermatitis is a delayed type of hypersensitivity of the skin, for which 
epicutaneous patch testing is regarded as the best method of coming to a diagnosis. 
It is based upon re-exposing the skin of the patient to suspected allergens under 
controlled conditions. It is a bioassay that reproduces contact dermatitis. The first 
epicutaneous tests were carried out by Jadassohn in 1895.1 Although it is more than 
100 years since the method of application was introduced, it is still the method of 
choice to establish contact allergy.2,3 In this review we discuss epicutaneous allergy 
testing and features of allergic contact dermatitis relevant for the patch test 
procedure.  
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History of patch testing 
The first detailed description of an epicutaneous allergy test was probably by a 
chemist, Städeler at the University of Göttingen, Germany in 1847. He described a 
method called the blotting paper strip, which he had devised to examine the effects 
triggered by Anacardium occidentale.1,4 In 1895 Josef Jadassohn introduced his 
“Application Method”5, inspired by Neisser’s work concerning contact dermatitis to 
iodoform and mercury derivatives.6 It was more than a decade before the concept of 
“allergy” was defined in 1906 by von Pirquet. After working with Jadassohn, Marion 
Sulzberger wrote his first major paper on the subject in 1931, together with Fred 
Wise: “The Contact or Patch Test in Dermatology”.7 This test is now commonly called 
patch test, a term introduced by Cooke in 1916. During the last decades of the 20th 
century a lot of effort has been put into standardization of materials and methods 
used in patch testing.8 Patch testing is cost-effective and if used appropriately 
reduces the length of the episode and/or the severity of the dermatitis and by that the 
cost of therapy in patients with allergic contact reactions.9 However, the accuracy of 
the test should be established in each patient; in other words does patch testing 
always accurately distinguish patients who do and don't have allergic contact 
dermatitis. 
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Clinical picture of allergic contact dermatitis 
The classic clinical picture of contact dermatitis is polymorph; an erythematous 
eruption maybe accompanied by vesicles, infiltration, edema, excoriations, scaling 
and sometimes crustae or excoriations. Usually it is accompanied by severe itching. 
The clinical picture or a positive patch test reaction resembles eczema in general, 
although it tends to be more sharply demarcated than the atopic or seborrhoeic form 
of dermatitis and the localization is more closely related to the area in contact with 
the responsible allergen. The classic positive patch test reaction is a miniature form 
of the same dermatitis: erythema, edema, and small, closely set vesicles, which often 
extends beyond the borders of the patch. 
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Etiopathogenesis 
Allergic contact dermatitis is a delayed type of hypersensitivity, a type 4 allergic 
reaction. However, it may not be a traditional type 4 hypersensitivity, due to the 
importance of the interaction between the irritant and antigenic properties of 
sensitizing chemicals in the development of allergic contact dermatitis.10 It is an 
inflammatory reaction, mediated by antigen specific T-lymphocytes. It can be divided 
into 3 phases: the sensitization, the challenge and, if the exposure stops, the 
resolution phase. 
Given the clinical nature of this article, we refer the readers to the article by Belsito 
DV et al.11. 
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The patch test procedure 
The present patch test technique is the result of a continuous process of 
development and improvement since its first application in the late 19th century12. 
Patch testing is only indicated if after history taking and clinical examination, allergic 
contact dermatitis is suspected. Epicutaneous patch testing is especially indicated if 
[a] a clear relationship is evident between the dermatitis and certain professional or 
other activities, [b] the dermatitis is confined to the hands or the feet, peri-orbital, 
around ulcera cruris or peri-anal dermatitis, [c] acute and wetting dermatitis of any 
localization and [d] any dermatitis that is therapy resistant, exist for over 3 months or 
worsens during topical treatment13. 
In the original test system the patches, tapes and allergens are supplied separately. 
Different patch test units are now commercially available; such as the Finn Chambers 
or van der Bend square chambers. These test chambers are filled manually. The 
modern adhesive tapes are acrylate and not colophony based, so the problem of 
colophony allergy has been eliminated.  
Standard patch test allergens are commercially available and have to be chemically 
defined and pure. The suppliers’ recommendations on storage are to be followed to 
minimize the risk of degradation due to humidity, air or light. Most preparations 
should be kept in a refrigerator and in the dark; those in diluted liquid preferably in 
dark bottles. The allergens should not be stored vertically, to prevent sedimentation 
and concentration changes of the allergens. 
The test preparation in petrolatum, kept in syringes, is applied directly onto the test 
chamber. Liquid test preparations are applied via a digital pipette to allow exact 
dosing. The preferred test site is the upper back, but the outer sides of the upper 
arms are also acceptable, especially when retesting. Only areas covered by clothing 
should be used, because some positive reactions may persist for several weeks and 
occasionally produce hypo- or hyperpigmentation. Removal of hair on the back is 
sometimes recommended for practical reasons, but it can contribute to the skin 
irritation. Oily skin can be degreased with a mild solvent, which must evaporate 
before applying the test strips.  
The skin of the back should not be treated with topical corticosteroids one week 
before testing. Preferably also oral corticosteroids should be avoided during testing, 
because they can suppress positive test reactions. The same goes for cytostatics 
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and cyclosporin. During one week before testing the skin should not be irradiated by 
the sun or artificial ultraviolet sources13.  
Each test site can be easily delineated with a marking paint, such as gentian violet, 
felt pens or the nearly colourless ‘ultraviolet’ paint, which shines bright yellow when 
exposed to black light.  
Patients should be informed about avoiding excessive exercise, showers, etc. to 
keep the test system dry. 
The patch test system is usually removed after 48 hours, as recommended by the 
International Contact Dermatitis Research Group14, and readings are done 20 
minutes after removal of the strips (Day 2) and after 72 (Day 3) or 96 hours (Day 4). 
For some test series it is preferred to read the tests once more after 7 days, not to 
miss the late reactions. Gold and certain therapeutic agents such as 
dermatocorticosteroids and neomycin have the tendency to appear later than reading 
day 2 or 415,16. Patients should be asked to note new positive reactions that arise 
after the readings at 96 hours and report them promptly. 
Occasionally some severe reactions can cause itching and burning, on which that 
patch can be prematurely removed without disturbing the others. 
The interpretation method recommended by the International Contact Dermatitis 
Research group (ICDG17) is:  
-    Negative reaction 
?+ Faint erythema only: doubtful reaction 
1+ Nonvascular erythema, infiltration, possibly papules: weak positive reaction 
2+ Vesicular erythema, infiltration, papules: strong positive reaction 
3+ Intense erythema and infiltration, coalescing vesicles, bullous reaction: extreme 
positive reaction 
IR Irritant reaction of different types 
NT Not tested 
 
The ?+ reaction is meaningful for an allergic reaction in 1-5%, the 1+ reaction in 20-
50% (depending upon the allergen), the 2+ reaction in 80-90% and a 3+ reaction is 
almost always allergic13. 
This method was developed to make the interpretation standard and easy, but the 
not all types of reactions fit this outline. Irritant reactions are said to be characterized 
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by fine wrinkling (‘silk paper’), erythema and papules in follicular distribution, 
petechiae, pustules, bullae or even necrosis and with minimal infiltration18.  
Irritant reactions are frequent, even to the standard series, because some of the 
concentrations have been chosen close to the irritancy threshold to diminish the risk 
of obtaining false-negative reactions. The frequency of irritant reactions is higher at 
day 2 as compared to later readings19. The morphology can differ from mild erythema 
to bullae. Sometimes it is indistinguishable from an allergic reaction and can be the 
cause of false-positive test reactions.  
Ready-to-use patch test systems are also available, preloaded by the manufacturer. 
They eliminate some of the variability in patch testing. 
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The allergens 
Different variables can be influenced to obtain an optimal bioavailability of the 
haptens: intrinsic penetration capacity, concentration, exposure time, vehicle and 
occlusivity of patch test systems. 
The penetration capacity depends upon the salt used. For example, there is a 
significant difference between the penetration of nickel achieved by nickel sulphate 
and nickel chloride20. 
It is important to find the ideal test concentration. Too high concentrations can cause 
irritation; too low concentrations are responsible for the false-negative test reactions. 
False-negative test reactions can also be due to the failure to duplicate the conditions 
present in the real dermatitis situation. The presence of the same allergens is often 
not enough; e.g. friction and sweating is an important contributing factor in shoe 
dermatitis, which are difficult to mimic during testing. In this case wet patch testing 
can be performed, keeping the leather patches from the patient’s shoes wet with 
artificial sweat or physiologic solution.  
The concentration of an allergen is normally given as a percentage, but in 
comparative studies with different salts of a substance it is essential to use the same 
molality21. 
Mostly an exposure time of 48 hours is chosen and all test strips are removed at the 
same time. 
Each allergen has its own optimal vehicle, but each vehicle has its own drawbacks. 
White petrolatum is the most widely used. It gives a good occlusion and keeps the 
allergens stable, but it can retain the allergen and irritate and even sensitize the 
skin22. Liquid vehicles such as water or solvents facilitate the penetration, but they 
evaporate, which interferes with exact dosing. Most test solutions with liquid vehicles 
must be freshly made. When using other, more sophisticated vehicles, containing 
alkalis, anionic detergents etc., the vehicle itself must also be patch tested to exclude 
the vehicle to be irritant. For example we found a high number of irritant patch test 
reactions to the vehicle DMSO/alc.abs. 50/50 used to patch test hydrocortisone 
acetate 1%23. Buffer solutions can be used for alkaline or acid allergens, to raise the 
test concentration24.  
Although the history and examination of a patient with suspected allergic contact 
dermatitis give clues to the responsible allergens, it is not always enough to test only 
the most suspected sensitizers, because the less suspected may also turn out to be 
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the real cause of the dermatitis25. There are approximately 3700 currently known 
allergens26. It’s obvious that it is impossible and undesirable to test them all. That’s 
why a small number of substances, considered to account for the majority of delayed 
hypersensitivity reactions, are grouped into a standard patch test series. Bruze et 
al.12 discussed the requirements to be fulfilled by a sensitizer to be included in the 
standard series. Demands on a sensitizer in the standard series are being common 
in the environment, contact allergy rate above 0.5-1.0% in routinely tested dermatitis 
patients, reliable patch test results, high degree of clinical relevance and minimal 
adverse effects, particularly patch test sensitization12. Generally 20-30 test 
preparations are grouped in a standard test series, which consist of chemically 
defined compounds, mixes of allergens, both natural and synthetic. These series are 
revised frequently to adapt to changes in exposure and introduction of new allergens 
onto the market and one should always remain critical towards the contemporary 
composition of the standard series. Minor variations are due to differences in culture, 
industrialization and use in different countries27,28,29. Testing with the test 
preparations in a standard series is said to detect 70% to 80% of all contact 
allergies13,30. The European Environmental and Contact Dermatitis Research Group31 
detected by the standard series hypersensitivity with a range from 37% to 73% of all 
contact allergies. Many international research groups now appreciate that these 
numbers may be artificially high. Indeed, the more one seeks out the cause of an 
allergy, the more likely one is to find an allergic cause. Cohen et al found that, among 
732 patients, only 23% had allergies detected solely by the standard series32. In 
another study by Sherertz and Swartz only 36% of positive reactions occurred to 
allergens in the standard series33. Indeed, there is mounting evidence that most 
standard series will detect much less than 50% of all relevant allergens. 
To evaluate the significance of specific exposures, different specific screening series 
are available. They can be divided into different categories based upon the 
occupation of the patient (e.g. hairdressing or bakery series), the localization of the 
dermatitis (e.g. shoe series), series of chemically related compounds (e.g. the 
acrylates or epoxy series) or functionally related compounds (e.g. corticosteroid 
series, cosmetics series). Overlapping occurs since many chemicals are present in 
several unrelated compounds. 
Mixes of four or five closely related chemicals are used to save time and space while 
patch testing. In the past several different mixes of allergens have been tried in patch 
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tests, but at present the most standard series contain mixes of “caine” anesthetics, 
parabens, fragrances and rubber chemicals. Caution must be observed in the exact 
composition of the mixes. The concentration of each chemical has to be sufficient. A 
sensitive patient can show a negative reaction to a mix, but a positive reaction to one 
of its ingredients tested separately, because the concentration of the ingredient in the 
mix is insufficient. The combination of the substances in the mix may not cause 
chemical reactions deactivating one of the ingredients or induce irritation to the skin. 
In cross-sensitivity, contact allergy caused by a primary allergen is combined with 
allergic reactions to other, chemically closely related substances. 
Products or materials brought by the patient and suspected of causing dermatitis 
should be tested with great caution. First of all it should be stated that totally 
unknown products should never be applied to human skin. Therefore one should 
always ask the patient to bring as much information on the product as possible, e.g. 
in the form of lists of ingredients, safety data sheets, etc. or they should be requested 
from the manufacturer. Usually some of the ingredients can be suspected more than 
the others, and if they are available from suppliers of patch test allergens, they 
should be tested in the vehicle and concentration as recommended by the supplier. 
Sometimes these tests remain negative and one can wonder whether the suspected 
product really causes an allergic contact dermatitis. Therefore it is recommendable to 
start with an open test, to minimize the risk of severe irritancy. If this is negative, 
occlusive patch testing can take place, usually starting at the lowest concentration 
and raising if the preceding test is negative. Depending on the likely irritant or 
sensitization potential of the product, it is recommended to start with concentrations 
of 0,001% or 0,01%. The ideal vehicle and test concentration for each product or 
chemical compound is difficult to discover, but help can be found in literature25. It is 
practical to apply it on a site that can be easily reached by the patient, to remove the 
patches if severe stinging or burning should occur. If the test remains negative after 
one day, the concentration can be raised for the next test. If the test is found positive 
in the patient, at least 10 unexposed controls should be tested to prove that the 
actual test preparation is nonirritant. As an example we mention 3 cases of dermatitis 
around a tracheostomy, caused by a cleansing tissue, which the patients used to 
remove glue from the skin around their tracheostomy. Not only the patients 
themselves showed severe patch test reactions to the cleaning tissue itself and a 
10% concentration of the extract, but 10 (50.0%) of the 20 healthy subjects tested 
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with the extract showed a + reaction to the 10% concentration after 72 hours, which 
was clearly an irritant reaction34. 
When solid products such as textiles, paper, rubber, plants or synthetics are 
suspected, it can be tested as thin, regular-sided, smooth sheets or extracts can be 
obtained by placing a sample of the material in water, synthetic sweat, ethanol or 
ether, and heating it up to 50ºC35. 
For most products intended for use on normal or damaged skin such as cosmetics, 
detergents, topical medicaments, etc. open tests and use test give probably more 
information on the pathogenesis of the patient’s dermatitis than an occlusive patch 
test does14. 
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Reproducibility, sensitivity and specificity 
The reproducibility of patch tests remains controversial. A series of papers has 
demonstrated good reproducibility of the patch test results, although some speak of a 
high percentage of non-reproducibility with the concomitant method of patch testing 
(patch testing simultaneously on both sides of the back). In literature we can find 
reproducibility percentages varying from 48% up to 96%36-46. Brasch J. et al. found 
that non-reproducibility of patch tests seems to be strongly allergen dependent. In 
their synchronous left- versus right-sided patch test study, the likelihood of non-
reproducible allergic reactions increased when more than four positive reactions were 
seen at the same time, and with another positive reaction located in close proximity 
to an allergic reaction. Other factors such as age, sex, atopy, sleeping habits, 
lipogenic skin activity, systemic medication, inflammatory dermatoses outside the 
back and internal medication (excluding corticosteroids) were of minor importance for 
patch test reproducibility47. Weaker patch test reactions seem to be less reproducible. 
Some of the variability is eliminated by the use of ready-to-use patch test systems. 
Gollhausen et al. found that such a system (TRUE test) eliminated about half of the 
non-reproducible reactions48 and Lachapelle et al. found that another preloaded 
system (Epiquick) was 95% reproducible in a left-to-right comparison49. 
The ideal patch test should give no false-positive or false-negative reactions. A false-
positive reaction is an irritant reaction with the same morphology as an allergic patch 
test reaction and therefore cannot be separated from reactions caused by 
sensitization. It can be caused by too elevated test concentrations, impure or 
contaminated test substances, irritant test substance or vehicle, current or recent 
dermatitis at the test site, current dermatitis at distant skin sites, pressure effects or 
mechanical irritation. 
False-negative reactions in the presence of a contact allergy can be due to too low 
test concentrations, test substance in insufficient amount or not released from the 
vehicle, test panels removed too soon, reading made too early, inappropriate 
comedication such as corticosteroids or due to a compound allergy. The latter is the 
condition in patients patch tested positive to formulated products, usually cosmetic 
products or topical medications, but tested negative to all the ingredients tested 
individually50. The mechanism can be irritancy of the original formulation, a false-
negative reaction to the ingredients or due to reaction products formed by the 
combination of the ingredients13,51,52. Irritants in the original formulation may increase 
  25 
the allergic contact dermatitis response and may explain the presence of contact 
dermatitis in patients with negative patch tests53. 
Pseudo compound allergy is due to faulty patch testing, illustrated by patch testing 
the individual ingredients at the usage concentrations in petrolatum, which are too 
low for many allergens. 
Quenching is the term used to describe the phenomenon of inhibition of sensitization. 
The concept was given life by the publication of Opdyke a quarter of a century ago54. 
The term quenching was employed to describe the complete abrogation of the 
sensitizing potential of 3 fragrance chemicals (cinnamal, citral and 
phenylacetaldehyde) by the presence of certain other fragrance chemicals (notably 
eugenol and limonene). In a recent publication Basketter concludes that no 
satisfactory (physico)-chemical or immunobiological basis for a quenching activity 
can readily be evinced, particularly since it would appear to be required to operate 
only during induction in man55. It is still a hypothesis, lacking substantive proof. 
Inappropriate comedication during patch testing includes topical and oral 
corticosteroids and immunomodulators. Treatment of the test site with topical 
corticosteroids can mitigate the responses obtained to a high degree56.  
Testing patients on oral corticosteroids is not recommendable. Comparison of 
intensity of reaction before and during treatment with corticosteroids has suggested 
that an important allergy cannot be missed under corticosteroids up to 20mg57,58,59. 
However, it is usually advisable to defer the test after corticosteroids have been 
stopped. The use of antihistamines as a contraindication for patch testing is not 
universally accepted. Some studies show that it is useless to stop antihistamines 
before patch testing, since clinical evaluation of tests is not hampered by a potent 
antihistamine60. Based upon echographic evaluation of patch test inhibition by the 
oral antihistamine loratadine, Motolese states that it is advisable for patients who are 
to undergo patch testing to be off loratidine (and probably also other oral 
antihistamines) to enable an evaluation that reflects their true sensitization state61. 
Nevertheless, in a multitude of other studies, the effects of oral antihistamines on the 
patch test response have been at best variable, and more frequently non-existent. 
This is particularly important since many patients are unable to avoid scratching the 
patch test area without the use of oral antihistamines, resulting in a much more 
confusing picture to interpret clinically. 
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The influence on patch testing of other immunomodulators such as orally or 
parenterally administered cytostatic drugs has not yet been clarified. Oral cyclosporin 
A inhibits expression of delayed contact hypersensitivity reactions in human skin62. 
Cyclosporin, which has a potent clinical impact on eczema, does not seem to modify 
the clinical score of intense reactions to contact allergens in patch tests63. The 
influence of topically applied cyclosporin A on patch test reactions is not clear64. 
Several studies have been reported on the suppressive effect of ultraviolet B (UVB), 
UVA sunlight and PUVA on contact dermatitis. However, studies that have tested the 
hypothesis that patch tests reactions have a seasonal variation due to the 
suppressive influence of sunlight, had found conflicting results65,66,67,68.  
The common screening allergens used to patch test patients thought to have contact 
dermatitis have a sensitivity of 77% and a specificity of 71%, very good for a 
bioassay69. 
From a statistical point of view, it is crucial to explore the patient's history carefully 
and exactly before performing patch testing: indiscriminate testing of many patients 
with a doubtful allergic origin of their skin problem will lead to many cases of wrongly 
diagnosed contact dermatitis70. 
Patch testing is as much art as it is science; we all are influenced by our clinical 
experience as well as by the literature71. Careful history taking combined with 
physical examination is extremely important in deciding whether or not to patch test 
and in deciding which materials should be tested in order to increase the predictive 
values of patch test results. 
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Relevance of positive patch test reactions 
Patch tests can be used to confirm a suspected allergic contact dermatitis and either 
to recommend avoidance of particular products or to recommend alternative products 
in a particular patient. 
The true rate of clinically relevant hypersensitivity in positive patch test reactions 
remains for a great part unknown. To know that a patient has been exposed to a 
sensitizer is insufficient to conclude that the positive patch test is relevant. There is 
always the risk to over- or underestimate the significance of positive patch test 
reactions. 
When a positive patch test reaction is found, an attempt must be made to fit it into the 
information obtained from the history and clinical examination. 
The relevance of the positive patch test reactions is not always easy to judge. For 
practical reasons it can be categorized as definite, probable or possible72. 
The major prerequisites for a contact allergy to be clinically relevant are 1\ exposure 
to the sensitizer and 2\ presence of a dermatitis which is understandable and 
explainable with regard to the exposure on the one hand and type, localization and 
course of the dermatitis on the other73. The problem is that one sensitizer causing the 
entire clinical picture of the dermatitis is rare. Mostly the cause is multifactorial, 
including irritant and constitutional influences. It is important to obtain sufficient 
information on the exposure to the suspected sensitizer, by questioning the patient’s 
own experience, analyzing data sheets on packages of used products, chemical 
analyses, etc73. Patient’s own suspected products are often tested and in case of a 
positive patch test reaction to one of them, the ingredients must be analyzed. Use 
tests are generally carried out in a standardized manner, but sometimes the 
diagnostic value may increase when the test simulates ordinary use conditions. In 
some products the concentration of the sensitizer is too low to elicit a patch test 
reaction, but sufficient to cause dermatitis in under use conditions with frequent 
exposures73.  
Often the substances giving rise to positive patch test results represent aggravating 
factors, but are not the cause of the primary dermatitis. This is especially true for 
reactions to medications, e.g. eardrops, used to treat a pre-existent skin disease, 
such as a chronic otitis externa74,75. 
Just as a positive reaction does not always mean that the primary cause of the 
dermatitis has been found, so a negative reaction does not always mean that the 
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dermatitis is not caused by contact allergic hypersensitivity. Standard series include 
only statistically common allergens; one must be constantly alert to the possibility of 
rare, exotic or new sensitizers25. 
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Adverse reactions 
The ideal patch test should cause as few adverse reactions as possible. 
- Irritancy itself can be considered as an adverse effect, especially the more severe 
reactions such as a chemical burn. Irritant patch test reactions are usually sharply 
demarcated, confined to the area covered by the patch.  
- The “excited skin syndrome" or ”angry back” means that there are many patch test 
reactions of which some are false-positive76,77. The cytokines released by 
inflammatory skin may enhance other patch test reactions78. It is a regional 
phenomenon caused by a/ subclinic dermatitis in an atopic patient or b/ the presence 
of a strongly positive patch test reaction, which produces a state of skin 
hyperreactivity in which other patch test sites become reactive, especially the 
marginal irritants. To confirm or deny the significance of the individual reactions, each 
substance should be tested again individually. 
- The “edge effect” is often an irritant reaction, with a more intense reaction at the 
periphery of the patch than in the center, due to an increased concentration of the 
irritant liquid at the margin. Sometimes a reaction with edge effect can be a false 
negative or doubtful patch test reaction to a corticosteroid. This is an eczematous 
reaction only apparent on the edge of the patch test site, particularly at the first 
reading. Probably the inflammation is still suppressed in the middle of the site where 
the concentration of the corticosteroid is the highest, while around the edges of the 
site, the corticosteroid diffuses through the skin, and the low concentrations allow the 
allergenic effect to prevail79. 
- Pustular patch test reactions are sometimes a manifestation of irritancy. Pruritus is 
often minimal or absent and the reactions usually disappear promptly, although they 
can occasionally persist for some days80. 
- Pressure reactions can occur, especially with the use of solid test substances and in 
patients with a tendency to dermographism. 
- A temporary flare of the existing dermatitis elsewhere on the skin can be due to a 
positive patch test reaction. 
- Numerous substances can cause contact urticaria, most frequently patients’ own 
materials brought from home or work to test; especially common are penicillin, 
balsam of Peru and phenylmercuric compounds. Katsarou states that almost all 
allergens of the European standard series can produce an immediate contact 
reaction. They are associated with delayed contact reactions to the same allergen in 
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a minority of the cases81. It should be considered if the patient complains of itching 
minutes after application of the patches. The mechanism may be immunologic or 
nonimmunologic. 
- Some sensitizers are known or suspected carcinogens, but the effect from the low 
doses applied to the back in patch testing is negligible.  
- Some metals and metal compounds used in patch testing can give systemic toxic 
effects82. 
- Hyperpigmentation may result from the inflammation alone, independent of the 
chemical response in certain patients83. Sometimes a severe reaction causes 
hyperpigmentation or total depigmentation. 
- Several chemicals are capable of inducing contact leukoderma. Contact 
leukoderma can appear following an allergic contact dermatitis and it may be 
indistinguishable from idiopathic vitiligo84. It occasionally appears during patch 
testing. Another example that one should be careful in testing products brought and 
used by the patient is the one of the dental acrylic resins tested "as is". Due to the 
high concentrations the patch test sites can remain vitiliginous for many months up to 
years85. 
 - Most dermatologists will not patch test pregnant women, although the teratogenic 
capacity of the patch test substances is probably nihil. The rationale is to avoid 
problems if there should be perinatal or congenital abnormalities due to other causes. 
However, before introducing new compounds into the test series, the teratogenic 
potential should be considered. 
- Patch test sensitization is considered to be the most serious adverse reaction of 
patch testing. It is detected by a flare-up reaction at the test site at least 10 days after 
the application86. On being repeated, the test is already positive at day 2-4. It is more 
likely that the flare-up reaction represents patch test sensitization than does the 
finding of a positive reaction to a substance that has previously been tested 
negatively. In the latter case, the patient may have been sensitized in the interval 
between the performances of the patch tests due to environmental exposure to the 
antigen87. Active sensitization is less likely to happen by using the lowest 
concentration of test substance required to cause a reaction. That’s another reason 
why one should beware of patch testing substances brought by patients. 
Nevertheless there is a risk of active sensitization from the standard series. Para-
phenylenediamine is an example of a compound in the standard series that has a 
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strong capacity to sensitize and therefore it is still subject of continuing debate 
whether it belongs in a standard series88. 
It should be stressed that a low sensitization level also may result in a (very) delayed 
contact allergic reaction89.  
- Anaphylactoid or anaphylactic reactions can occur from e.g. penicillin. It is therefore 
not recommended for routine patch testing. Radioallergosorbent tests (RAST) seem 
the most safe in case of suspected immediate reactions (type I allergic reaction). In 
the diagnosis of non-immediate reactions both patch and intradermal tests could be 
useful90,91. 
Kamphof et aldemonstrated that patch testing can cause subjective complaints, like 
tiredness, shakiness or feeling unwell, especially when positive patch tests are 
present92.  
A lot of adverse reactions were summarized above, but it has to be noted that the 
overall risk-benefit equation of patch testing is in favour of the benefit, if performed 
correctly and at proper indication. 
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Other tests 
- Open tests are recommended as the first step when testing poorly defined or 
unknown substances, brought by the patient. This concerns especially gels, liquids or 
creams, suspected of producing irritant reactions if occluded. Cosmetics such as 
perfumes, aftershave lotions and hairsprays are the prototypes in this kind of testing. 
It is applied undiluted to the normal skin twice a day for at least two days. The outer 
aspect of the upper arm or the retroauricular area is the recommended site for open 
tests. It should be left uncovered and the application has to be discontinued if any 
irritation arises. The test is read after 15 to 30 minutes to detect contact urticaria. 
Otherwise the readings are done as with the closed patch tests. A negative open test 
indicates that an occlusive patch test can be preformed with the substance without 
expecting severe irritant reactions. 
- The provocative use tests are performed to confirm positive patch test reactions. 
The suspected agent is used onto the normal skin as it was before, to evaluate if a 
relapse occurs. If no reaction occurs, the test may be considered negative25. It is 
important to evaluate the clinical significance of the ingredients of a formulated 
product found positive by patch testing. 
- The repeated open application test (ROAT) is a use test, performed on the outer 
aspect of the upper arm, the antecubital fossa or the scapular area of the back over 
an area of approximately 3 centimeter in diameter. The substances are applied twice 
daily for 7 days. A positive response usually appears on day 2 to 4. The patient is 
instructed to stop the application of the test substances when a reaction is noticed93. 
ROAT’s should sometimes be applied longer than 7 days, particularly if low 
concentrations of the allergen are present and/or when there is a low sensitization 
level. Some patients only react after 2 or 3 weeks in a ROAT. 
- Prognostic patch testing differs from diagnostic patch testing. Clinicians routinely 
perform diagnostic patch testing, but prognostic patch testing is the province of 
corporate research and development departments and, in the United States, contract 
laboratories94. The purpose of this type of patch testing is to determine the irritant or 
allergic contact dermatitis potential of an ingredient or a product. 
- ‘Preventive’ or ‘prophetic’ patch testing, for example on potential employees. It is 
not at all recommendable. It is not a proper indication and it exposes the patient 
unnecessary to the different allergens and by that to the adverse effects possible. 
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- Photopatch testing should be used to investigate patients with clinically suspected 
photoallergic contact dermatitis (PACD). PACD is caused by photochemical 
conversion of a certain agent into a contact allergen, mainly induced by UVA. 
Particularly plant derivatives, fragrances, antiseptics and sunscreen agents are 
known for photosensitization. The latter have now become the most common 
photoallergens, due to the extensive use during the last decades. Diagnostic 
procedures for PACD include MED testing and photopatch testing. The differential 
diagnosis of PACD includes: airborne allergic contact dermatitis, phototoxic 
reactions, chronic actinic dermatitis, seborrhoeic dermatitis, polymorphic light 
eruption, variants of systemic lupus erythematosus and cutaneous porphyrias. 
The photopatch test procedure can vary between centers, but in generally goes as 
follows. The test materials are applied to the back in a duplicate set for 24 hours. One 
test site is irradiated with UVA (320-400nm) and the other serves as an unirradiated 
control. The tests are read immediately and 24, 48 and 72 hours after UVA 
irradiation. 
- In vitro assays: 
Presently, there is no in vitro technique available to replace epicutaneous patch 
testing.  
The lymphocyte transformation test: Defibrinated blood for in vitro lymphocyte studies 
is obtained from the patient. The lymphocytes are incubated and cultivated with 
various concentrations of allergens. A positive control of proliferation is obtained with 
a purified protein derivative. Lymphocyte transformation in control and antigen-
treated cultures is measured by 3H-thymidine incorporation into lymphocyte DNA 
after 5d cultivation.  
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Conclusions 
We conclude that epicutaneous patch testing is a useful procedure if it is well 
performed and if it is performed for the right indication. 
However, the problems concerning the relevance of these tests remain. A careful 
history taking and attention for the clinical picture are key actions to facilitate the 
interpretation of the clinical relevance of the epicutaneous patch test results. 
Maybe we can expect an evolution in epicutaneous patch testing in the 21st century. 
To diminish the problems of the relevance a proper selection of patch test chemicals 
should be made, adapted to the individual patient's problems.  
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Chapter 2 
The risk of active sensitization to PPD. 
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Abstract 
BACKGROUND: 
Para-phenylenediamine (PPD) and para-aminoazobenzene are strong sensitizers. By 
the patch test procedure, the patient may be sensitized to these agents. Combined 
testing of para-compounds may increase the risk of active sensitization. 
OBJECTIVE: 
We studied the % of positive patch test reactions and their relevance. In order to 
assess the risk of active sensitization we compared the % of relevant reactions of 
both early (48/72 hours) and late (7 days) reactions. We also compared the % of 
positive patch test reactions to PPD and their relevance if simultaneously tested with 
para-aminoazobenzene.  
METHODS: 
We studied the patch test reactions to PPD in the routine series in 2058 patients. In a 
group of 678 patients we tested PPD and para-aminoazobenzene simultaneously. 
RESULTS: 
4,3% and 3,1% of the patients reacted to PPD respectively with and without 
simultaneous testing with para-aminoazobenzene. We estimated the reactions as 
relevant in 21,1% and 39,7% respectively with and without simultaneous testing with 
para-aminoazobenzene. We considered none of the late reactions as relevant. 
CONCLUSION: 
We found a high proportion of relevant patch test reactions to PPD, but sensitization 
to PPD by the patch test procedure is a risk. We state that routine series should not 
contain PPD. The high number of irrelevant late positive reactions strongly suggests 
active sensitization. Moreover PPD is not a ubiquitous allergen and can be tested on 
a non-routine basis if industrial exposure to para-compounds is suspected or if a 
specific localization (e.g. head or feet) prompts the testing of PPD. Testing PPD 
combined with para-aminoazobenzene does lead to a slight increase in positive 
reactions to PPD (p<0.25) and to an increase in irrelevant reactions (p<0.10). 
 
Keywords 
PPD; para-aminoazobenzene; patch testing technique; active sensitization; clinical 
relevance
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Introduction 
Para-phenylenediamine (PPD) is used in dyes for hair, fur, leather, printer’s ink, fax 
machines, photographic products, X-ray film fluids and lithography. Para-
aminoazobenzene is mainly used as a dye in the textile and clothing industry. These 
compounds are strong sensitizers. By patch testing, a subject may be sensitized to 
these agents. Late reactions may be an indication of active sensitization (1) and may 
be an argument for deleting a compound from standard series. A higher frequency of 
irrelevant late reactions compared to the rate of irrelevant reactions after 48-72 hours 
may also be an argument for active sensitization. Combined testing of para-
compounds may increase the risk of active sensitization. 
We studied the % of positive reactions and the relevance of positive early and late 
patch test reactions to PPD with and without simultaneous patch testing with para-
aminoazobenzene in order to assess the risk of active sensitization to PPD.  
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Materials and Methods 
We studied 2058 patients, ages 8 to 85 years, patch tested with PPD in the period 
September 1995 – September 1999 at the Department of Dermatology of the 
University Hospital Nijmegen, The Netherlands retrospectively (group1). PPD was 
tested as 4-phenylenediamine free base at 1,0% PET, the standard series PPD. The 
tests were performed using van der Bend patch test chambers, affixed with Fixomull 
Stretch tape. Tests were removed after 2 days (D) and the results read according to 
ICDRG guidelines at D2 and D3. We advised the patients to come back later if a late 
reaction occurred. 
We defined a positive patch test reaction as relevant if the patient had had skin 
contact with a para-compound and experienced worsening of the dermatitis after the 
contact. The localization of the dermatitis also had to correspond with the area of skin 
contact. We categorized the relevance of the positive patch test reactions as definite, 
probable or possible (2). Past relevance was also considered. 
We compared the results to PPD in this group with the results to PPD in a group of 
678 patients, 421 women (62%) and 257 men (38%), aged 14-79, tested with PPD 
and para-aminoazobenzene simultaneously between October 1992 and January 
1994 (group2). 
Differences in relevance were tested for significance using a Chi-square test. 
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Results 
63 patients (3,1% of group1), 45 women (71%) and 18 men (29%), reacted to PPD in 
the standard series. 
On D3 37 reactions to para-phenylenediamine were read as +, 14 as ++ and 4 as 
+++. 3 reactions that were considered as doubtful on D3 became evident between D3 
and D7 and 2 were read as + and 1 as ++ on D7. 5 patients showed late reactions 
(later than 7 days), 3 a + reaction and 2 a ++ reaction (Table 1). 
We grouped the 63 positives into hand and foot dermatitis, dermatitis localized to the 
face and/or scalp and a group with various localizations, such as the flexures, the 
whole body, the penis, the external auditory canal and the axillae (Table 2). 
38 (60,3%) patients, 14 men and 24 women, had hand and/or foot dermatitis. In 17 of 
them (44,7% of 38) the positive reaction to PPD was considered to be probably or 
definitely relevant. 14 of them also reacted to patch tests with their own shoes. Here 
PPD used in dyes for leather could have been the responsible allergen. In 2 patients, 
both hairdressers, hair dyes seemed responsible. 1 patient had a definitely relevant 
reaction to the ink of a copying machine. 
14 (22,2%) patients, 2 men and 12 women, had dermatitis on the face or scalp. In 8 
of them (47,1%) the positive reaction to PPD was considered to be probably or 
definitely relevant since there was also a positive reaction to their own hair dyes.  
In the group, consisting of 11 (17,5%) patients, 2 men and 9 women, with various 
localizations of the dermatitis, we could not find any relevance for the positive 
reactions to PPD. 
Probable or definite relevance in the group with hand and foot dermatitis was 44,7%, 
in the group with dermatitis on the face or scalp 47,1% and in the third group we 
could not find any relevance. The overall probable or definite relevance after 48 
hours was 39,7% (Table 2). 
In the group of 678 patients tested with PPD and p-aminoazobenzene simultaneously 
4,3% showed a positive reaction to PPD and 2,5% a positive reaction to p-
aminoazobenzene. 
After 48 hours there were 0 + reactions to p-aminoazobenzene, 3 ++ reactions and 3 
+++ reactions. In this group, 11 patients returned to report a positive reaction later 
than 7 days, 2 with a + reaction, 8 with a ++ reaction and 1 with a +++ reaction. The 
% of self-reported, late reactions is 7,9% in group1 versus 64,7% in group2. In the 
latter group the overall probable or definite relevance was only 11,8%, because only 
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2 of the 17 patients had a clear history of allergic contact dermatitis from dark colored 
textiles. The overall probable or definite relevance for PPD versus p-
aminoazobenzene was 39,7% versus 11,8%. 
All of the 17 patients positive to p-aminoazobenzene also had a positive reaction to 
PPD. In the group2 12 patients were positive to PPD, but not to p-aminoazobenzene. 
In this group the % positive to PPD was ([17+12]/678) 4,3% with a relevance of 
21,1% (Table 3). 
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Discussion 
We found a high percentage of positive reactions with frequent relevance for early 
reactions to PPD, especially in the groups with dermatitis of the hands and feet or of 
the face and scalp. We found a significantly lower relevance at the 10% level in the 
group with late reactions to PPD (using a Chi-square test). A higher frequency of 
irrelevant late reactions compared to the rate of irrelevant reactions after 48-72 hours 
is an indication of active sensitization. 
The major prerequisites for a contact allergy to be clinically relevant are 1\ exposure 
to the sensitizer and 2\ presence of a dermatitis, which is understandable and 
explainable with regard to exposure, and type, localization and course of the 
dermatitis (3). 
There were no relevant patch test reactions to PPD in the 7 patients (group1 and 2) 
who self reported a positive reaction later than 7 days. This strongly suggests that 
these patients were sensitized by the epicutaneous application of PPD during patch 
testing.  
However there is an inter-individual variability in eliciting a reaction to the PPD 
molecule on patch testing, with regard to both exposure time and concentration 
required (4). Subjects have been shown to react to lower concentrations of metabolic 
breakdown products of PPD than to the actual PPD molecule itself (5). This could 
also explain late reactions in individuals, not due to sensitization. 
Arnold et al. (6) studied the effect of adding para-aminoazobenzene to the European 
standard series. It may increase the sensitivity of detecting contact allergy to dyes, 
used in textile and clothing, but it also carries the risk of active sensitization.  
Demands on a sensitizer in the standard series are (a) being common in the 
environment, (b) a contact allergy rate above 0.5-1.0% in routinely tested dermatitis 
patients, (c) reliable patch test results, (d) a high degree of clinical relevance and (e) 
minimal adverse effects (7).  
Our opinion is that late positive patch test reactions to PPD may not be relevant in a 
large number of cases. Since it is a strong sensitizer, giving rise to active 
sensitization, it should be removed from the standard series. 
Combined testing of para-compounds may increase the risk of active sensitization 
and combined sensitizations to different azo dyes, probably based both on true 
cross-sensitization and on simultaneous positive reactions, have frequently been 
described (8). However, our results do not show a significantly higher % of positive 
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patch test reactions to PPD in the period of combined testing of the para-compounds 
(4,3% versus 3,1% when only PPD was tested). 
We conclude that para-aminoazobenzene does not belong in a standard series and 
that the same can be stated for PPD. Patch test sensitization is considered the most 
serious adverse reaction of patch testing and therefore PPD should be tested only 
when indicated. The patient’s history and clinical examination gives a clue to para-
compounds as the responsible allergens, which then can be tested on an aimed 
basis. 
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Table 1: Reactions to PPD evaluated according to the International Contact 
Dermatitis Research Group: 
after 72 h. appearing between 
D3 and D7 
later than 7 days       9/1995 – 9/1999 
(group1) 
# of 
patients       
probable 
or definite 
relevance 
# of 
patients 
probable 
or definite 
relevance 
# of 
patients 
probable 
or definite 
relevance 
+ reactions 37 15(40,5%) 2 1(50,0%) 3 0(0,0%) 
++ reactions 14 5(35,7%) 1 1(100,0%) 2 0(0,0%) 
+++ reactions 4 3(75,0%) 0 - 0 - 
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Table 2: The 63 positives of group1 divided into three groups based on the clinical 
appearance of the dermatitis: 
Localization: # of patients % patients probably or 
definitely relevant 
hands and feet 38 60,3 17 44,7% 
face and scalp 14 22,2 8 47,1% 
various 11 17,5 0 0% 
Total: 63 100 25 39,7% 
 
 
Table 3: Comparison of the results of the 2 patch test groups: 
Period of testing group1 
9/1995 – 9/1999 
group2 
10/1992 – 1/1994 
Compound tested PPD PPD para-
aminoazo 
benzene 
Number of patients tested  2058 678 678 
Number of positive reactions  63 29 17 
Percentage of positive reactions 3,1% 4,3% 2,5% 
Overall probable or definite 
relevance after 48 hours 
39,7% 21,1% 11,8% 
Self-reported late reactions 5 patients 
(7,9%) 
2 patients 
(6,9%) 
11 patients 
(64,7%) 
Probable or definite relevance of 
late reactions 
0% 0% 0% 
 
 
  52 
Chapter 3 
Evidence-based diagnosis in patch testing. 
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Abstract 
Evidence-based medicine (EBM) is defined as the integration of the best research 
evidence with clinical expertise and patient values. On the basis of principles of EBM, 
we can conclude that patch testing is only cost-effective if patients are selected with a 
clear clinical suspicion of contact allergy and only if patients are tested with 
chemicals relevant to the problem (high pre-test probability). Random patch testing 
(low pre-test probability) should be discouraged.  
Proper pre-test probability assessment can only be done in expert centres, since 
problem-based testing requires both thorough knowledge of the patch test procedure, 
as well as knowledge about potential sensitizers in a specific environment. 
 
Key words 
Evidence-based medicine, patch testing 
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Evidence-based diagnosis 
Evidence-based medicine (EBM) was introduced in clinical practice to fulfil the daily 
need for valid, up-to-date information. However, the EBM approach has been the 
subject of discussion since its introduction. In the 1980s, the evidence-based 
approach was founded on the best available research data coming from randomised 
controlled trials. The conflict between the results of studies and the individual case 
became, however, apparent. Nowadays EBM is defined as the integration of the best 
research evidence with clinical expertise and patient values. The best evidence, as 
coming from well-designed studies, should be matched with the individual case (1). 
EBM can (and should) not only be applied to therapeutic intervention, but also to 
diagnostic procedures. EBM can help us to assess the validity, accuracy and 
potential harm of a diagnostic procedure in relation to its costs. EBM applied to 
diagnosis and screening can be referred to as evidence-based diagnosis (EBD). 
Patch testing: 
Patch testing is a bioassay to investigate contact sensitization. It is a relatively cheap 
and safe procedure to determine a causal link between sensitization to a specific 
agent and allergic contact dermatitis. It has, however, several pitfalls (2). Although 
patch testing is the gold standard in diagnosing contact allergy, a positive reaction as 
read by international guidelines cannot automatically be assumed as proof of 
sensitization (2,3). In patch test clinics, agents are often tested in standard and 
screening series. Sensitization not suspected by history and/or clinical examination 
can be detected in this way. Requirements to include a chemical in a standard series 
have been formulated by Bruze et al. (3). In addition, ready-to-use materials relevant 
to the specific leisure activities and working conditions can also be selected for patch 
testing.  
In series, chemicals are tested in well-defined concentrations in order to reduce the 
chance of false-positive and false-negative reactions. However, in series many 
substances are tested simultaneously, which may because of multiple testing, give 
rise either to false-positives or to reactions not relevant to the specific situation. If 
only a small panel of chemicals is tested, selected on the basis of history of 
exposure, relevant allergies may be missed.  
In this paper, we will discuss the validity of a patch test in the context of the principles 
of EBD in relation to the patch testing procedure. We will demonstrate the differences 
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in post-patch test probability if an agent is tested either randomly (standard series) or 
selectively chosen (problem based). 
We will also discuss the considerations relevant to the decision to test in a specific 
patient. Based on the application of EBD, we propose a problem-oriented, 
individualized approach carried out in centres with dermatological and occupational 
(environmental) expertise. This approach must guarantee a safe and cost-effective 
policy of patch testing. 
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According to Sackett et al we have to answer 3 questions about patch testing if we 
apply EBD (1): 
 
1. What is the validity of the patch test procedure? 
2. What is the importance (accuracy) of the patch test procedure? 
3. Can I apply the test in this specific situation? 
 
What is the validity of the patch test procedure; is patch testing the gold 
standard? 
Validity is the ability of a test to detect or measure the aimed biological phenomenon 
(1). In the case of patch testing: does a patch test predict contact sensitization (Type-
IV hypersensitivity) or another biological phenomenon like contact irritancy? It is more 
than 100 years since Jadassohn carried out the first epicutaneous tests and the 
method of patch testing is still the first choice in diagnosing contact allergy (4). A 
patch test is a bioassay where contact with a relevant allergen under controlled 
conditions is supposed to reproduce a delayed type of hypersensitivity. However, 
patch testing is influenced by many variables and, although substances are tested 
under controlled conditions, the allergic nature of the patch test reaction cannot be 
assumed beyond all doubt. For most allergens, however, positive patch test 
reactions, if done and read according to international guidelines, are predictive for 
contact sensitization (5,6). The validity of patch testing may, therefore, be considered 
as good for many chemicals, if tested under controlled conditions and in the proper 
concentration, but may be considered as poor for substances which are tested at a 
concentration eliciting an irritant reaction or with substances with unknown skin 
irritant potential.   
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What is the importance of the patch test procedure; does patch testing 
discriminate? 
Under ideal conditions, a diagnostic test predicts with 100% certainty the presence or 
absence of a disease. Most tests, including patch tests, are however not capable of 
predicting the truth beyond any doubt.  The ability of a valid test to distinguish 
between patients who have a disease or not (the importance or accuracy of the test) 
is dependent on the sensitivity and specificity of the diagnostic procedure and the 
prevalence of the disease. Sensitivity is defined as the proportion of the people with 
the target disorder with a positive test, and specificity as the proportion of people 
without the target disorder who have a negative test. In the case of patch testing, 
sensitivity indicates the number of sensitized patients with a positive test and 
specificity the number of patients not sensitized to an allergen with a negative test for 
the specific allergen. Data on the sensitivity and specificity of positive patch test 
results are scarce. Nethercott reported that sensitivity and specificity of patch testing 
approximates to 70% (7). Although the concepts of sensitivity and specificity are 
needed to determine the accuracy, they are in themselves not very useful. The 
clinician is more interested in the odds that a person has the disease or not, and to 
what extent a diagnostic test can help to estimate the probability of disease after 
testing. For that purpose we have to delineate the concepts of likelihood ratio, pre-
test and post-test odds and pre-test and post-test probability (see Table 1).  
Without any additional information, pre-test probability equals the prevalence of a 
disorder. If more information becomes available from history taking, clinical 
investigations and diagnostic tests, then the probability of having or not having a 
disease may come close to 100%. Post-test probability is calculated from the post-
test odds (post-test odds/(post-test odds + 1) and post-test odds is defined as the 
pre-test odds multiplied by the likelihood ratio of a test. To calculate the post-test 
odds we need the well-known concepts of sensitivity and specificity. The positive 
likelihood ratio is defined as sensitivity/(1 – specificity). It is, in fact, the ratio of the 
chance of a positive test result in a person with the disease, versus the chance of a 
positive test result in a person without the disease (a “good” test has a high likelihood 
ratio). If, for the purpose of clarification, we follow the estimate of sensitivity and 
specificity of patch testing in general of Nethercott, this ratio will be 0.7/(1 – 0.7) = 
2.33.  
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Thus, the post-test odds is the ratio between the probability that contact allergy is 
present after a positive patch test, versus the probability that allergy is absent. The 
post-test probability is the probability that contact allergy is present after a positive 
patch test. We will show how disappointing the post-patch test probability is with the 
presumed sensitivity and specificity as estimated by Nethercott.  
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Pre-patch test probability of contact allergy 
The prevalence of contact sensitivity to allergens is difficult to determine. In the 
general population it is not known because hardly any epidemiological data are 
available (8). In subgroups of patients with dermatitis, the prevalence can be 
estimated using clinical and scientific data (9-12). The prevalence of contact 
sensitization will, however, vary significantly depending on the specific characteristics 
of the subgroup.  
In order to estimate the value of patch testing we can assess pre-test odds and 
probability and post-test odds and probability, either in patients without or in patients 
with clinical suspicion of contact dermatitis. In the first situation we can use the 
prevalence data obtained by patch testing with the European standard series. These 
data, although overestimating prevalence by patient selection, come closest to the 
prevalence of contact allergy in the general population. In this situation, patch testing 
is performed in a patient population without any specific suspicion of contact allergy 
(routine testing). For our calculations, we used the patch test results of the patients 
who visited our department of occupational dermatology from 1995-2000 for patch 
testing (see Table 2). In the second situation we have, based on clinical and 
epidemiological grounds, a clinical suspicion of contact allergy. To demonstrate the 
importance of a test with a particular sensitivity and specificity we have to estimate 
pre-patch test probability. We select a pre-test probability of 50% for explanatory 
reasons. However, any other percentage can be used instead, since this probability 
depends on the specific additional information in the individual patient. 
 
Post-patch test probability of contact allergy 
Table 3 shows the post-patch test probability data using the likelihood ratio 
corresponding to a sensitivity of 70 % and a specificity of 70% as estimated by 
Nethercott (7). These results make clear that post-patch test probabilities do not 
justify random testing as suggested by Bruze et al. (3). In Table 3 the post-patch test 
probabilities are also depicted if an allergen is tested in a patient with a clinical 
suspicion of 50% of having a specific sensitization. Although the probability does not 
come close to 100%, the patch test is much more informative in this case, as is 
shown in the table. It should, however, be realised that sensitivity and specificity data 
of patch testing may be allergen specific and may vary with the severity of the patch 
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test reaction. This means that the importance of the test may be higher in one 
allergen than in another, and higher in ++ and +++ reactions versus + reactions. 
Moreover, we can increase the post-test probability if we perform more diagnostic 
tests (multilevel testing). After each test the pre-test probability for the subsequent 
test increases. Repeated patch testing or testing with (chemically) related substances 
may in this way increase post-test probabilities (1,13). 
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Relevance of a contact allergy 
If contact allergy is suspected with reasonable certainty, the next step is to judge the 
relevance of the sensitisation for the patient’s dermatitis. It is not possible to provide 
absolute rules for the determination of relevance. Based on the presence of the 
putative chemical in materials which come into contact with the skin either 
occupationally or during leisure activities, the distribution of the skin lesions and the 
effect of elicitation by exposure and healing of the dermatitis by avoidance, positive 
patch test results are judged as possible, probable or certainly relevant. Sensitization 
may have taken place in the past and may be irrelevant to the present dermatitis. 
Recently, we estimated the relevance of positive patch test reactions in otitis externa 
as 10% for the current dermatitis (14).  
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Can I apply the test in this specific situation; is patch testing cost-effective and safe in 
this specific patient? 
The patch test procedure must be cost-effective and safe enough to justify 
application in the individual patient. As we have shown, cost-effectiveness depends 
heavily on the clinical suspicion of contact allergy. To answer that question we have 
to judge the pre-test probability. Moreover, we have to estimate the risk of side 
effects from the procedure (active sensitization, excited skin, severe patch test 
reactions and any mutagenic and teratogenic risks). Finally, the procedure must 
satisfy patient values. The discomfort of the procedure must be accepted by the 
patient and must be compensated for by the possible advantages as judged by the 
patient (1).  
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Conclusion 
Patch testing is safe and cost-effective if patients are selected properly. Random 
patch testing should be discouraged since randomly performed tests are hardly 
informative. If positive results from random tests are at hand, these results should 
only be considered as relevant after careful history taking and physical examination. 
If any doubt persists testing with chemically related substances or repeated testing 
might be of help (multilevel testing). 
A problem-based approach can only be done in expert centres, since problem-based 
testing requires both thorough knowledge of the patch test procedure and its pitfalls, 
as well as knowledge about potential sensitizers in a specific environment. Only in 
these centres, staffed by dermatologists experienced in both clinical and diagnostic 
aspects of contact allergy, can a sufficient likelihood ratio and post-test probability be 
obtained. 
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Tables 
 
Table 1 
 
Target disorder 
(allergic contact dermatitis) 
Totals 
present absent  
Diagnostic test result 
(patch test) 
positive a b a+b 
 negative c d c+d 
 Totals a+c b+d a+b+c+d 
 
 
 
Sensitivity   = A/(A+C) = 0.7*  
 
Specifity   = D/(B+D) = 0.7* 
 
Positive likelihood ratio LR + = sens/(1-spec) = 0.7/(1-0.7) = 2.33* 
 
Negative likelihood ratio LR - = (1-sens)/spec = (1-0.7)/0.7 = 0.43* 
 
Positive predictive value  = A/(A+B) 
 
Negative predictive value  = D/(C+D) 
 
Prevalence   = (A+C)/(A+B+C+D) 
 
Pre-test odds   = prevalence/(1 - prevalence) 
 
Post-test odds   = pre-test odds x likelihood ratio 
 
Post-test probability   = post-test odds/(post-test odds + 1) 
 
* according to Nethercott (7)
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Table 2 
Percentage of positive patch test results, European standard series 1995-2000, 
Nijmegen (n=1701). 
 
  1.   
  2.  
  3.   
  4.    
  5.   
  6. 
  7.   
  8.   
  9.  
10.   
11.    
12.  
13.    
14.   
15.
16. 
17. 
18.  
19.   
20.   
21.  
22.   
23. 
Potassium dichromate  
4- Phenylenediamine free base  
Thiuram mix  
Neomycin sulfate  
Cobalt chloride  
Benzocaine   
Nickel sulfate   
Quinoline mix   
Colophonium   
Paraben mix   
N-Isopropyl-N-phenyl-4-phenylenediamine 
Lanolin alcohol   
Myroxylon Pereirae resin (Balsam of Peru) 
Epoxy resin   
Mercapto mix 
4-tert-Butyl phenol formaldehyde resin 
Quaternium-15  
Primin 
Fragrance mix 
2-Mercaptobenzothiazole 
Sesquiterpene lactone mix 
Formaldehyde 
Methylchloroisothiazolinone + 
methylisothiazolinone (Kathon® CG) 
5.70 
2.87 
2.50 
1.38 
7.06 
0.75 
14.73 
  0.48 
  3.52 
  0.64 
  1.01 
  4.16 
  7.38 
  0.96 
  2.14 
  2.29 
  1.01 
  0.37 
18.10 
  1.60 
  0.85 
  2.18 
  2.35 
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Table 3 
Post patch-test probabilities  
  Post patch-test 
probability if pre-test 
probability equals 
prevalence in patch 
test clinic 
Post patch-test 
probability if 
pre-test 
probability 
equals 50% 
  1.   
  2.  
  3.   
  4.    
  5.   
  6. 
  7.   
  8.   
  9.  
10.   
11.    
12.  
13.    
14.   
15.
16. 
17. 
18.  
19.   
20.   
21.  
22.   
23. 
Potassium dichromate  
4- Phenylenediamine free base  
Thiuram mix  
Neomycin sulfate  
Cobalt chloride  
Benzocaine   
Nickel sulfate   
Quinoline mix   
Colophonium   
Paraben mix   
N-Isopropyl-N-phenyl-4-phenylenediamine 
Lanolin alcohol   
Myroxylon Pereirae resin (Balsam of Peru) 
Epoxy resin   
Mercapto mix 
4-tert-Butyl phenol formaldehyde resin 
Quaternium-15  
Primin 
Fragrance mix 
2-Mercaptobenzothiazole 
Sesquiterpene lactone mix 
Formaldehyde 
Methylchloroisothiazolinone + 
methylisothiazolinone (Kathon®CG) 
12.3% 
6.4% 
5.6% 
3.2% 
15.0% 
1.7% 
28.7% 
  1.1% 
  7.8% 
  1.5% 
  2.3% 
  9.2% 
  15.7% 
  2.2% 
  4.8% 
  5.2% 
  2.3% 
  0.9% 
34.0% 
  3.6% 
  2.0% 
  4.9% 
  5.3% 
70.0% 
“ 
“ 
“ 
“ 
“ 
“ 
“ 
“ 
“ 
“ 
“ 
“ 
“ 
“ 
“ 
“ 
“ 
“ 
“ 
“ 
“ 
“ 
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Chapter 4 
Relevance of positive patch test reactions to the fragrance mix. 
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Abstract 
Fragrances are an important cause of allergic contact dermatitis. We assume that the 
fragrance mix (FM), used as a tool in the European standard series to diagnose 
fragrance sensitization, detects 70-80% of the fragrance allergic patients. A positive 
patch test reaction cannot be regarded as proof of contact sensitization and not in all 
cases contact sensitization proves to be relevant to the skin disease. The FM has an 
irritant potential. This means that weakly positive reactions will have a bigger chance 
to be irrelevant than strong reactions. Here we report on the relevance of patch test 
reactions of different strength to the FM materials and on predictive factors to this 
relevance in order to help the clinician to judge positive patch test reactions more 
accurately. Our findings show that if any doubt exists on the relevance of a weakly 
positive reaction to the FM, re-testing the FM and its ingredients adds to the accuracy 
of the diagnostic procedure. In a well-selected population with a high pre-test 
probability this additional testing is appropriate both in terms of cost-effectiveness as 
in terms of patient acceptance. 
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Introduction 
Fragrances are an important cause of allergic contact dermatitis and are generally 
recognized as one of the 5 most common causes of contact sensitization (1). The 
fragrance mix (FM), containing 8 fragrances and sorbitan sesquioleate, is used as a 
screening tool for fragrance sensitivity in the European standard series. World wide 
the reported prevalence of positive FM reactions ranges from 5% to 14% (2-4). The 
studies show a rising trend, which may be the result of an increased use of 
fragrance-containing cosmetics and toiletries. About 3000 different fragrance 
materials of synthetic and natural origin are used in perfumery. We assume that the 
FM detects 70-80% of patients with a fragrance allergy (1). Studies on the specificity 
of the FM are not available.  
Altered skin care, changed cleansing habits and an increased incidence of 
(subclinical) atopic dermatitis may change the vulnerability to irritant skin reactions. 
An increase in false positive (irritant) patch test reactions may contribute to the rising 
trend of positive reactions (5,6). Not only the FM is an indicator for fragrance allergy, 
but Balsam of Peru and Colophony are indicator substances as well (7). New 
markers for fragrance hypersensitivity have been searched for and tested, for 
example Lyral®, ylang ylang, lemon grass oil, jasmine, narcissus, etc. These 
materials have been claimed as putative ingredients for the FM, but only Lyral® 
proved to be a good candidate (2). Addition of Lyral® into the FM might increase the 
sensitivity, however very likely at the expense of the specificity. Today Lyral® is 
added to the European standard series by many dermatologists as a separate patch 
test material.   
Because of the marginal irritant potential of the FM, weakly positive reactions in 
particular may not be regarded as proof of contact sensitization (low specificity of the 
test). This means that weakly positive reactions should be evaluated more carefully 
for relevance to the particular skin disease. Here we report on the relevance of 
positive patch tests of different strength to the FM materials and on presumed 
predictive factors to this relevance in order to help the clinician judge (weak) positive 
patch test reactions more precisely.  
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Materials and Methods 
In the period January 2002 – December 2002 138 patients, who were consecutively 
patch tested in the participating centers to the standard series and showed a 
doubtfully positive (?+) or positive reaction (1+ to 3+) to the FM, were entered in the 
study. We determined the relevance of the patch test reactions on (i) the patient’s 
experience with an eczematous reaction or worsening of a pre-existing dermatitis 
after contact with fragrances (ii) the correspondence with the area of skin contact with 
the localization of the dermatitis and (iii) the patch test results of patient’s own 
cosmetics and toiletries. We categorized the relevance of the patch test reactions as 
none, possible, probable or definite for the positive reactions taken together (1+ 
through 3+) and for the ?+, 1+, 2+ and 3+ reactions separately according to Rietsche 
and Fowler in Fisher’s Contact Dermatitis (8). Then we re-patch tested these patients 
with the standard series FM and a battery of the 9 FM ingredients at specified 
concentrations in petrolatum (table 1). The study was carried out at different 
departments of dermatology in hospitals both in the Netherlands and in Belgium. The 
patients were re-tested the earliest 4 weeks after the first patch tests. 
The re-testing was done in the same hospital where the first test was performed and 
the same investigator read the results. We used Van der Bend® or Hayes® test 
chambers, affixed with Fixomull Stretch® tape. Test material was removed after 2 
days and the results were read according to ICDRG guidelines on day 2 (D2) and on 
day 3 (D3) (9). 
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Statistics 
We determined the predictive value on relevance of the (first) FM of (1) a repeated 
FM test, (2) a test with the FM ingredients, (3) the test results of balsam of Peru and 
colophony, and (4) a (history of) atopic dermatitis in two ways. Firstly, each predictor 
was related with the relevance of the first FM test in a two by two contingency table 
(Table 2). In the calculation ‘not relevant’ or ‘possibly relevant’ was considered as not 
relevant and ‘probably’ and ‘definitely relevant’ as relevant. The strength of this 
relation was quantified by the sensitivity, specificity, positive predictive value (PPV) 
and negative predictive value (NPV). Also, in order to summarize the diagnostic value 
of the variable in a single measure, the diagnostic odds ratio (DOR) with 
corresponding 95% confidence interval (95% CI) was calculated. In a diagnostic 
setting, the DOR reflects the ratio of the Likelihood Ratio of a positive test result 
(LR+) and the Likelihood Ratio of a negative test result (LR-). In case a test does not 
have any diagnostic value, the OR (LR+/LR-) is close to 1.0. In case a test has strong 
diagnostic value the OR will become extremely high. 
Secondly, in order to evaluate the diagnostic value of combinations of the predictors, 
we re-analyzed the data using logistic regression analyses with relevance of the first 
test as dependent variable. For the optimal combination of predictors, we again 
report the (adjusted) DORs with corresponding 95% confidence intervals (Cis). 
Finally, we calculated the post-test probabilities of a relevant positive FM test, taking 
in account the significantly contributing predictors. The Statistical Package for Social 
Sciences (SPSS), release 11.0.1 (November 2001), was used for analysis.  
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Results 
On the first test to the FM, readings at day 3 showed in 40 patients (29%) a ?+ 
positive reaction, in 42 (30,4%) a 1+ reaction, in 28  (20,3%) a 2+ reaction and in 28 
(20,3%) a 3+ reaction. In 46 (33,3%) patients there was a history or actual clinical 
signs of atopic dermatitis. 47 (34,1%) had a positive reaction to balsam of Peru, 14 
(11,1%) had a positive reaction to colophony. The percentage of relevant ?+, 1+, 2+ 
and 3+ reactions were 25.0%, 40,5%, 71,4% and 75,0% respectively. Thus the 
percentage of relevant reactions increased significantly with the strength of the 
reaction (p < 0.001). 
On re-testing, the FM yielded positive patch test reactions at D2 in 110 (79,7%) and 
at D3 hours in 121 (87,7%) patients. In the 17 (12,3%) patients with negative 
reactions on re-testing at D3 there were no positive reactions to the battery of the FM 
ingredients.  
Of the 121 patients with a confirmed positive reaction to the FM, 99 (81,8%) showed 
a positive reaction to at least one of the ingredients tested. Table 1 shows the 
numbers of positive reactions to the battery of the 9 FM ingredients. Remarkably, 16 
patients reacted to sorbitan sesquioleate. 
One patient had an angry back and reacted to all the compounds. 
Table 2 shows the relation between each predictor and the relevance of the first FM 
test, as quantified by the sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) in a two by two contingency table. 
Based on the results from the univariable analyses, the repeated FM test (D3), a 
positive reaction to one or more of the fragrance ingredients and atopic dermatitis 
were entered into a multivariable logistic regression model. To make this analysis 
possible, one patient who scored positive to the second test was assumed to have 
not a relevant first test. The results are summarised in Table 3. Atopic dermatitis did 
not have a significant additional value in the multivariable model (model 1) and was 
removed in model 2. The probability of a relevant first test for the 4 combinations with 
the two significantly contributing additional tests (repeated FM test and test with 
ingredients) is summarized in the table 4 for all tests and for the weak (?+ and 1+) 
and strong (2+ and 3+) reactions separately. This table shows that only in case of ?+ 
and weakly positive reactions and not in case of strong (2+ and 3+) reactions 
additional testing adds to the accuracy of the patch test results. 
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Discussion 
The international Contact Dermatitis Research Group (ICDRG) recommends a 1+ to 
3+ scoring system. Weak and questionable reactions are recorded by a question 
mark (?+) and irritant reactions are recorded as IR. The paradigm is that 1+ to 3+ 
reactions are identified as positive reactions, indicating contact sensitisation (8).  
However, a patch test is a bioassay and there are no distinctive morphological criteria 
to distinguish contact allergy from an irritant reaction. The validity of the patch test is 
generally regarded adequate if the test is done according to the guidelines. This 
study reveals clinical relevance of ?+, 1+, 2+, and 3+ reactions to the FM in 
respectively 25%, 40,5% and 71,4% and 75% of the patients.  
Based on these findings we state that the validity of the FM patch test procedure 
varies with the strength of the test reaction. A positive reaction on re-testing to the 
FM or to one of the ingredients adds significantly to the probability of a relevant test 
in case of ?+ and 1+ reactions. A positive test to Balsam of Peru or colophony does 
not predict relevance of the (weakly) positive FM reactions. Having atopic dermatitis 
may have a slight predictive value on the relevance of the (weakly) positive FM 
reactions (see table 2). 
To differentiate a contact allergic patch test reaction from an irritant patch test 
reaction on clinical grounds may be interesting for increasing the validity of the 
diagnostic test. The clinician is, however, more interested in the accuracy and the 
relevance of the findings in relation to the skin complaints. Does the test accurately 
predict the presence or absence of contact reactions and are the findings relevant to 
the skin disease? The accuracy of the patch test as prove of sensitisation cannot be 
determined precisely, since reliable confirmation of contact sensitisation by an in vivo 
or in vitro test is lacking. However, the relevance of the test can be assessed on 
clinical grounds (history, physical examination, testing patient’s own cosmetics and 
follow-up). Our findings and data published elsewhere show a limited relevance of 
the FM patch test outcome (10).  This study indicates that the reactions to sorbitan 
sesquioleate in the mix are partly responsible for this. 
Which patient has to be tested to the FM and which patient has to be re-tested with 
the FM and her ingredients? The low (estimated) FM sensitivity in an unselected 
population and low specificity of the FM patch test procedure (estimated in this study) 
makes the FM patch test less useful than desirable, since only in a patient with a high 
pre-test probability of having a contact reaction, patch testing adds substantially to 
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the chance of making a correct diagnosis (11). Based on the findings in this study, 
additional testing (re-testing with the FM, testing with the ingredients of the FM) in 
case of weakly positive (+? and 1+) reactions improves the accuracy.  
However, a diagnostic procedure must not only be valid, accurate and relevant, but 
should also meet patient values (12). Repeated patch testing is time-consuming for 
the patient. Therefore, only in a well-selected population with a high pre-test 
probability this additional testing seems appropriate both in terms of cost-
effectiveness as in terms of patient acceptance.  
In this group of selected patients, the test procedure may be very rewarding, because 
the patients, pending the new European legislation on ingredient labelling, can be 
instructed to avoid specific fragrance substances.   
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Table 1: Positive reactions to the FM  ingredients 
 
Test compounds*: Number 
Cinnamic alcohol 5%  2 
Cinnamic aldehyde 2%  21 
Eugenol 5%  15 
Alpha-amylcinnamic aldehyde 5%  8 
Hydroxycitronellal 5%  14 
Geraniol 5%  20 
Isoeugenol 5%  19 
Oak moss 5%  12 
Sorbitan Sesquioleate 20%  16 
 
*In petrolatum 
 
 
 
Table 2: Sensitivity, specificity, positive predictive value (PPV) and negative  
predictive value (NPV) and the diagnostic odds ratio (DOR) with 95%     
confidence interval of predictive variables/tests to the relevance of the   
fragrance mix. 
 
 
Prognostic 
variables 
Se 
(%) 
Sp 
(%) 
PPV (%) NPV (%) DOR (95% CI) 
Positive retest D1 93 33 57 82 6.2 (2.2-17.4) 
Positive retest D2 100 24 56 100 > 20 * 
Reaction to 
ingrediënt(s) FM 
91 47 63 85 9.2 (3.5-24.1) 
Balsam of Peru 38 70 55 54 1.4 (0.7-2.9) 
Colophony 7 87 36 49 0.5 (0.2-1.7) 
Atopic dermatitis 41 74 61 57 2.0 (1.0-4.2) 
 
• Exact DOR and 95% CI cannot be calculated because there were no   
      patients who scored positive to the second test and who did not have 
      a relevant first test. 
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 Table 3:  
 
Logistic regression analysis: diagnostic odds ratio (DOR) with 95%     
confidence interval of predictive variables/tests to the relevance of the   
fragrance mix. 
 
 
Test p-value DOR (95% CI) 
Model 1   
Positive retest fragrance 
mix (D2) 
0.11 6,3 (0.7-58.8) 
Positive retest to 
ingredient(s)  
0.008 4.1 (1.4-11.5) 
Atopic dermatitis 0.31 1.5 (0.7-3.3) 
   
Model 2   
Positive retest fragrance 
mix (D2) 
0.11 6.0 (0.6-55.6) 
Positive retest to 
ingredient(s)  
0.004 4.5 (1.6-12.4) 
 
 
 
Table 4: The post-test probability of a relevant first test with the fragrance 
     mix for the 4 combinations of the two significantly contributing tests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positive re-
test 
ingredient(s)  
Positive 
re-test 
FM 
Probability of 
relevant first test (?+ 
and 1+ reactions)  
Probability of 
relevant first test (2+ 
and 3+ reactions)  
Probability of  
relevant first  
test (all reactions)  
- - 0.06 Did not occur 0.06 
- + 0.27 Did not occur 0.27 
+ - Did not occur Did not occur Did not occur 
+ + 0.49 0.73 0.63 
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Chapter 5 
Relevance and reproducibility of patch-test reactions to corticosteroids. 
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Abstract 
We present our patch test findings with dermatocorticosteroids during the period 
1995-1999. We retrospectively studied the % of doubtful and positive reactions to 
each allergen in our corticosteroid series and assessed the relevance of these 
reactions. To assess reproducibility, we retested 15 patients with doubtful or positive 
reactions in 1999. 
The % of + or ++ reactions on D2-D3 and D7 ranged from 0.0% to 0.9% for most of 
the compounds tested. Hydrocortisone acetate 1% alc.abs./DMSO 50/50 showed a 
much higher % of positive reactions. Most of these reactions were not relevant and 
therefore probably due to the irritant nature of the vehicle. 
An overall reproducibility of 47.2% was obtained. 100.0% of the non-reproducible 
patch test reactions were not relevant. Definite relevance was much higher in the 
reproducible + or ++ reactions than in the reproducible doubtful reactions: 100.0% 
and 18.2%, respectively. 
We conclude that the mean % of + and ++ reactions to the corticosteroid series on 
D2-D3 is 0.5%, with an overall reproducibility of 47.2%. Tixocortol pivalate and 
budesonide proved to be important markers for dermatocorticosteroid allergy. 
 
Key words 
corticosteroids; patch testing technique; reproducibility; retesting; clinical relevance; 
medicaments; tixocortol pivalate; budesonide; cross-sensitivity; contact allergy
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Introduction 
Contact sensitization to dermatocorticosteroids is considered to be a relevant clinical 
problem (1,2). The prevalence of positive patch tests is high, though varies between 
studies (3). Retesting of positive reactions shows concordance depending on the 
score of the positive reaction (4). In contact allergy to topical corticosteroids, not only 
the patch test reactions but also the clinical picture can be deceptive. We studied the 
relevance of doubtful and positive patch test reactions to corticosteroids, in order to 
interpret the patch test results better. Moreover, we studied the reproducibility by 
retesting positive tests, and related (non)concordance to the relevancy of the tests. 
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Materials and Methods 
The clinical relevance of doubtful and positive patch test reactions to 
dermatocorticosteroids tested from 1995 till 1999 in the Department of Dermatology 
of the University Medical Center Nijmegen, The Netherlands, was assessed by 
interviewing the tested patients. Special emphasis was put on the question whether 
avoiding the specific (putative) allergen (and cross-reacting chemicals) had made any 
difference to the severity of their dermatitis. We categorized the relevance of the 
positive patch test reactions as definite, probable, possible or none (5). The 
corticosteroids that we tested during that period are listed in Table 1. The patch test 
vehicle for hydrocortisone acetate (DMSO/alc.abs. 50/50) was also patch tested, 
because of the reported high rate of positive reactions, probably caused by the irritant 
nature of the vehicle (6). 
We also retested 15 patients with positive reactions in 1999, to assess the 
reproducibility of doubtful and positive reactions. Patch testing was done using Van 
der Bend chambers affixed with Fixomull stretch tape. Tests were removed after 2 
days (D) and results read according to ICDRG guidelines at D2, D3 and D7. 
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Results 
Table 2 shows the dermatocorticosteroids tested, the number of patients tested with 
each substance (budesonide and tixocortol pivalate are also tested in our additional 
series, explaining the higher number of tested patients), the number and % of 
doubtful reactions and + or ++ positive reactions on D2-D3 and on D7. The number 
and % of estimated relevancy is also shown.  
The % of + or ++ reactions on D2-D3 and D7 ranged from 0.0% to 0.9% for most of 
the compounds tested. 
2 out of the 14 compounds tested produced significantly higher %s of positive 
reactions: hydrocortisone acetate 1% DMSO/alc.abs. 50/50 and the vehicle 
DMSO/alc.abs. 50/50: 6.1% and 5.2%, respectively, on D2-D3. 
We found cross-reactions primarily within certain groups of corticosteroids: 4 cross-
reactions between hydrocortisone, tixocortol pivalate and budesonide; 1 cross-
reaction between betamethasone dipropionate, dexamethasone and budesonide and 
1 cross-reaction between clobetasol-17-propionate, hydrocortisone-17-butyrate and 
budesonide. We had 2 cross-reactions between budesonide and tixocortol pivalate; 1 
cross-reaction between budesonide and prednisone and 1 cross-reaction between 
budesonide and triamcinolone acetonide. 
After retesting the 15 patients with positive reactions in 1999, we compared the 
sequential test results (Table 3). If a doubtful or positive reaction to a test substance 
was obtained in 1999, but not in 2000, the result was regarded as nonreproducible. 
We found an overall reproducibility of 47.2% (17 of the 36 reactions in 1999 were 
reproducible). 
We found 100.0% of the nonreproducible patch test reactions to be not relevant. The 
definite relevance was much higher in the reproducible + or ++ reactions than in the 
reproducible doubtful reactions: 100.0% and 18.2%, respectively. 
On retesting we found 5 new doubtful reactions, all of which were irrelevant. In 
contrast, 3 new + or ++ reactions were found that were definitely relevant. 
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Discussion 
Considering our results, we can state that the mean percentage of + and ++ reactions 
to the corticosteroid series on D2-D3 is 0.5%, with a significantly higher percentage 
of doubtful reactions at the same reading time. In addition, the relevance of the + and 
++ reactions is estimated higher than that of the doubtful reactions. 
None of the non-reproducible reactions was relevant. 
Bircher et al. found a frequency of positive patch tests to corticosteroids ranging from 
0.2 up to 5% in a multicenter study of patients undergoing routine patch tests in 
Switzerland. This is in agreement with our results. However, we found an overall 
reproducibility of 47.2%, whereas Bircher et al. found a concordance of 70-98% on 
retesting, depending on the corticosteroid and the score of the positive reaction (4).  
Of the 14 compounds tested, only hydrocortisone acetate 1% DMSO/alc.abs. 50/50 
and the vehicle DMSO/alc.abs. 50/50 produced significantly higher percentages of 
positive reactions on D2-D3, with a significant lower percentage of estimated 
relevance. These are presumably irritant patch test reactions. Moreover, we could 
find no (cross-)reactions with other compounds tested. 
Since most patients have used different corticosteroids, not only cross-reactions are 
possible, but also concomitant and/or subsequent sensitization. 
We found 11 reproducible doubtful reactions, of which 5 (45.5%) had probable or 
definite relevance. This could be due to the 'edge' effect. False negative or doubtful 
patch test reactions can be due to the anti-inflammatory effect of the corticosteroid 
itself, the effects of vasoconstriction and vasodilatation and the ‘edge’ effect (7). This 
is an eczematous reaction apparent only at the edge of the patch test site, 
particularly at the first reading. The inflammation is probably still suppressed in the 
middle of the site where the concentration of the corticosteroid is the highest, while 
around the edges of the site, the corticosteroid diffuses through the skin, and the low 
concentrations allow the allergenic effect to prevail (8). This implies that these 
doubtful reactions would also be relevant and hence reproducible.  
Boffa et al. (9) states that at least 90% of individuals with a reaction on patch testing 
to budesonide are allergic to another corticosteroid. This is true of 50% of those 
allergic to tixocortol pivalate, the other proposed marker of corticosteroid allergy. We 
can indeed come to this conclusion: 10 of the 11 patients (90.8%) with + or ++ 
reactions to budesonide also had positive patch test reactions to other corticosteroids 
tested. The same can be said of 6 of the 8 patients (75.0%) with + or ++ reactions to 
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tixocortol pivalate. Tixocortol pivalate and budesonide proved to be important 
markers for dermatocorticosteroid allergy (2). 
The available evidence suggests that, with corticosteroids, the allergen is not the 
steroid itself but a degradation product. Degradation within the skin might therefore 
be a factor that influences the development of cross-reactivity (10). 
The pattern of cross-reacting corticosteroids in our tested patients is accordingly to 
the groups of cross-reacting corticosteroids described by Coopman et al. (11). 
In contrast to what is generally accepted, the reading on D7 was of minor importance 
in our series. Only 1 additional + reaction was found on D7. It was a reaction to 
betamethasone dipropionate and it was considered definitely relevant. This is in 
contrast to the findings of Isaksson et al. (12), who state that without a late reading 
(D7) up to 30% of contact allergy to corticosteroid markers is missed. 
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Table 1: Dermatocorticosteroids tested in the period 1995 - 1999. 
Test compounds: 
betamethasone dipropionate 1% alc. abs. 
budesonide 0.1% pet. 
clobetasol-17-propionate 1.0% pet. 
Desoximethasone 1% alc. abs. 
dexamethasone 1% alc. abs. 
hydrocortisone 1.0% pet. 
hydrocortisone acetate 1% DMSO/alc.abs. 50/50 
hydrocortisone-17-butyrate 0.1% pet. 
Prednisone 1% alc. abs. 
prednisolone 1.0% pet. 
tixocortol pivalate 1.0% pet. 
triamcinolone acetonide 0.1% pet. 
betamethasone-17-valerate 0.12% pet. 
DMSO/alc.abs. 50/50 
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Chapter 6   
 
The relevance of positive patch test reactions in chronic otitis externa 
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Abstract 
We patch tested 79 patients suffering from chronic otitis externa with the European 
standard series, a standard series of topical medication, own topical materials and 
additional series if appropriate. 35 patients (44,3%) showed positive reactions. 
Twenty-two patients (27,8%) reacted to a topical aural preparation or its ingredients. 
Nine (11,4%) had used topical aural preparations during the last 4 months before 
testing. Nine (11,4%) had used these topical drugs in the outer ear in the past, but 
not during the last 4 months. Four (5,1%) had never used topical aural preparations. 
Thirteen patients (16,5%) showed reactions to substances not relevant to the 
treatment of the auditory canal, such as reactions to nickel sulfate and the fragrance 
mix. 
The relevance of positive patch test reactions to ingredients of topical ear medication 
should be defined carefully. A positive patch test can be relevant to an allergic 
contact reaction superimposed on a pre-existent skin disease. However, a substantial 
number of our patients with positive patch test results did not use topical aural 
preparations during the last 4 months before testing. In this group the test results are 
relevant to future treatment policy, but not to the dermatitis actually present. 
 
Key words 
relevance, patch testing, chronic otitis externa 
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Introduction 
Otitis externa is a broad term for a disease state that includes inflammation or 
infection of the external auditory canal and auricle. It may be divided into an acute 
and a chronic form. The acute form is usually a local infection of the lateral one third 
of the external auditory canal. The pathogenic organism is usually Staphylococcus 
aureus; less frequent other Staphylococcal or Streptococcal species are cultured (1).  
The major organisms isolated in chronic suppurative otitis media are Pseudomonas 
aeruginosa (27.2%), followed by Staphylococcus aureus (23.6%) (2).  
Chronic otitis externa can be part of an endogenous skin disease as psoriasis, atopic 
or seborrheic dermatitis, but can also be idiopathic. Exogenous factors in chronic 
disease are irritants, allergens and microbes. A prolonged use of topical preparations 
may lead to allergic reactions (3). Epicutaneous patch testing is used to rule out a 
contact allergy. The relevance of a positive patch test reaction should, however, be 
defined carefully. Therefore, we patch tested 79 patients with chronic otitis externa in 
order to assess the relevance of positive patch test reactions to the actual skin 
disease as well as to future treatment policy. 
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Materials and Methods 
We studied a group of 79 patients, 45 women (57%) and 34 men (43%), whose ages 
ranged from 3 to 85 years. The study was carried out during the period July 1995 - 
July 1999 at the Department of Dermatology of the University Hospital Nijmegen, The 
Netherlands. The 79 patients suffered from chronic otitis externa that persisted for at 
least 4 months to over 30 years. 50 patients (63%) had been referred by an 
otorhinolaryngologist, because of the chronic otitis externa that did not respond to 
topical therapy. 
Information on prior and concomitant skin diseases was obtained by taking the 
patient’s history and by physical examination. 
The 79 patients were subjected to patch testing with the European standard series, a 
standard series of topical medication (table 1), own topical materials and additional 
series if appropriate (table 2). The tests were performed using van der Bend Patch 
Test Chambers, affixed with Fixomull Stretch tape. The test substances were 
removed after 48 hours and the test results were read according to international 
guidelines at 48, 72 and 96 hours and after 7 days. 
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Results 
35 patients (44,3%) showed positive reactions. Twenty-two patients (27,8%) reacted 
to a topical aural preparation or its ingredients. Nine of them (11,4%) had used 
topical aural preparations during the last 4 months before testing. Nine others 
(11,4%) had used these topical drugs in the outer ear in the past, but not during the 
last 4 months. The other four of them (5,1%) had never used topical aural 
preparations. Thirteen patients (16,5%) showed reactions to substances not relevant 
to the treatment of the auditory canal, such as reactions to nickel sulfate and the 
fragrance mix. 
Table 1 presents the different allergens in our standard series of topical medication, 
the number and the percentage of positive reactions and the number of late positive 
reactions (after 7 days).  
Positive reactions to agents tested in the European standard series, additional series 
or with own materials, are presented in table 2.  
27 patients (34,2%), 9 men en 18 women, had a history of atopic dermatitis, allergic 
rhinitis or asthma. 70 patients were subjected to intracutaneous tests which were 
positive in 32 (40,5%). 
Psoriasis in the past or actual psoriasis lesions was present in 9 patients (11,4%). 
Irritant contact dermatitis was found in 2 patients (2,5%), atopic dermatitis in 8 
(10,1%) and seborrheic dermatitis in 20 (25,3%). One patient had a pronounced 
dermatitis on the hands with an accompanying allergy to nickel.  
12 patients (15,2%) used a hearing aid. In 1 patient the epicutaneous tests proved a 
relevant allergy to the plastic pieces of the device. Additional patch testing showed 2+ 
and 3+ reactions to phenyl salicylate (1,0% PET), benzoyl peroxyde (1,0% PET), 
tricresyl phosphate (5,0% PET), triphenyl phosphate (5,0% PET) and Resorcinol 
monobenzoate (1,0% PET). Another patient had developed an allergic contact 
dermatitis due to the golden coating of his hearing aid. Patch testing showed a 1+ 
reaction to goldsodium thiosulfate.  
In the group of 22 patients with positive patch test reactions to ingredients of topical 
medication only in 4 patients (5,1%) the discontinuation of the topical aural 
preparations resulted in a remarkable improvement of the otitis externa. We consider 
this a relevance of 18,2% (4 out of 22). 
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Discussion 
These results make clear that the relevance of positive patch test reactions to 
ingredients of topical ear medication should be defined carefully. A positive patch test 
can be relevant to an allergic contact reaction superimposed on a pre-existent skin 
disease. However, a substantial number of our patients with positive patch test 
results did not use topical aural preparations for the last 4 months. In this group the 
test results are relevant to future treatment policy, but not to the dermatitis actually 
present. 
35 patients (44,3%) showed positive reactions, of which 22 patients (27,8%) to either 
topical medication or its ingredients. If the skin reacted to topical medication (17 
patients), one or more ingredients also proved to be positive, mostly the 
aminoglycoside antibiotics or the steroids. Consequently the rate of false positive 
reactions to topical ear medication was probably minimal. For example, one patient 
reacted to Synalar Biotic eardrops and Kenalog tincture. The responsible allergens in 
the topical agents were the triamcinolonacetonide (1+) and the benzalkonium 
chloride (2+). Another patient reacted to Synalar Biotic eardrops, Otosporin eardrops, 
Sofradex eardrops and Panotile eardrops. He had also positive reactions to 
Bacicoline-B (1+) and Neomycin Sulfate (2+). One patient reacted only to Otosporin 
eardrops and Neomycin Sulfate (1+); another to Sofradex eardrops and Neomycin 
Sulfate (2+). One patient had a positive reaction to Locacorten-Vioform eardrops, 
Clioquinol eardrops and Clioquinol (1+). 
In the group of 22 patients reacting to ingredients of topical medication only in 4 
patients (this is 18,2% out of 22 patients) the results were relevant for the actual 
disease at the time of testing. The results of the other patients may either have been 
relevant in the past or may be relevant for future treatment policy, but are not relevant 
to the present otitis externa. It is possible that positive epicutaneous test results are 
overestimated and considered relevant to the pre-existent skin disease in other 
studies. Van Ginkel et al. (4) found 56% relevant positive reactions in patch testing 
because of chronic otorrhoea. The reasons for this difference in number of relevant 
positive reactions can be a geographical difference in topical aural medication use 
and an other way of defining the relevance of a positive patch test reaction. 
Chronic otitis externa can be part of an endogenous skin disease as psoriasis, atopic 
or seborrheic dermatitis, but can also be idiopathic. In a small group of patients an 
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allergic contact dermatitis may also be the cause of a chronic otitis externa, although 
it is very likely to be superimposed on a pre-existent skin disease.  
As in previous studies (3 - 7), the most important allergen is Neomycin, which cross-
reacted with other aminoglycoside antibiotics tested. 
A contact allergy, superimposed on a pre-existent otitis externa, is often iatrogenic. 
Topical combination preparations for patients suffering from chronic otitis externa are 
often prescribed without ruling out endogenous skin disease or exogenous factors as 
irritants, allergens and microbes. These preparations often contain aminoglycoside 
antibiotics and steroids. In some cases there might not be an infection and then the 
antibiotic is superfluous. When there is an infection superimposed on a pre-existent 
endogenous skin disease, it is often enough to treat the latter e.g. with topical or 
systemic steroids. In acute otitis externa or infection with resistant bacteria oral 
antibiotics may be more appropriate and a lot safer in regard to contact allergies. 
Topical corticosteroids might not be indicated in case of infection. Prescribing 
antibiotics should be done more restrictive and when there is no evident infection it 
might be safer to use a local disinfectant e.g. acetic eardrops. 
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Table 1: standard series of topical medication: 
Test compound                                                # ⊕        % ⊕      # ⊕ after 7d 
Propyleneglycol         5,0% PET or 10%aqua 0 0 0 
Polyethyleenglycol “8000”            4,0% aqua 1 1,3 0 
Benzalkonium chloride                  0,1% PET 2 2,5 0 
Sodium pyrosulphite                      2,0% PET 3 3,8 0 
Kenalog tincture1 3 3,8 0 
Synalar Biotic eardrops2 4 5,1 2 
Locacorten-Vioform eardrops3 1 1,3 0 
Otosporin eardrops4 5 6,3 2 
Panotile eardrops5 4 5,1 2 
Sofradex eardrops6 5 6,3 4 
Terracortril eardrops7 0 0 0 
Clioquinol eardrops8 1 1,3 0 
Bacicoline-B9 3 3,8 1 
 
1Per g: triamcinolonacetonide 2 mg; Acid. Salicylicum 20 mg; Benzalkonium chloride 
5 mg in alcohol 70% 
2Per ml: fluocinolonacetonide 0,25 mg; polymyxin B 10.000 IU; neomycin 3,5 mg; 
propyleneglycol 400 mg 
3Per ml: flumetason 0,2 mg; clioquinol 10 mg; in polyethyleneglycol 
4Per ml: neomycin 5 mg; polymyxin B 10.000 IU; hydrocortison 10 mg; 
methylhydroxybenzoate 1 mg 
5Per ml: fludrocortison 1 mg; neomycin 10 mg; polymyxin B 10.000 IU; lidocaïn 40 mg 
6Per ml: dexamethason 0,5 mg; framycetin 5 mg; gramicidin 0,05 mg; 
phenylethylalcohol 5 mg 
7Per ml: oxytetracycline 5 mg; polymyxin B 10.000 IU; hydrocortison acetate 15 mg 
8Per ml: clioquinol 10 mg in macrogol 
9Per ml: colistin 250.000 IU; bacitracin 500 IU; hydrocortison acetate 10 mg 
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Table 2: allergens in the other test series, which have been found positive in this 
study: 
Triamcinolon acetonide                         0,1% PET 2 2,5 
Benzocaïne                                           5,0% PET 1 1,3 
 
1Dutch Pharmacopoeia 
2miconazol 2% in propyleneglycol 
 
 
 
 
 
 
 
 
 
 
 
Test compound #⊕ % 
Neomycin Sulfate                                20,0% PET 12 15,2 
Nickel Sulfate                                        5,0% PET 9 11,4 
Fragrance mix                                       8,0% PET 8 10,1 
Carbamix                                               3,0% PET 5 6,3 
Caïne mix II                                         10,0% PET 4 5,1 
Jodium                                            1,0% Alc. 96% 4 5,1 
Acid. Salicylicum                                   5,0% PET 3 3,8 
Balsam of Peru                                   25,0% PET 2 2,5 
Budesonide                                           0,1% PET 2 2,5 
Thiuram mix                                          1,0% PET 2 2,5 
Cobalt Chloride                                     1,0% PET 2 2,5 
Ethylenediamine Dihydrochloride         1,0% PET 1 1,3 
Hydrocortison                                        1,0% PET 1 1,3 
Hydrocortison acetate            1% Alc.Abs./DMSO 1 1,3 
Betamethasondipropionate                 1% Alc.Abs 1 1,3 
Chloracetamide                                     0,2% PET 1 1,3 
Clioquinol                                               5,0% PET 1 1,3 
Mercapto mix                                         1,0% PET 1 1,3 
2-Mercaptobenzothiazole                      2,0% PET 1 1,3 
Epoxy resin                                            1,0% PET 1 1,3 
Wool alcohols                                      30,0% PET 1 1,3 
Mercuric Chloride                                  0,1% PET 1 1,3 
Chlorhexidin Digluconate                     0,5% aqua 1 1,3 
Daktarin crème 1 1,3 
Pantene pro V shampoo 1 1,3 
Acetic eardrops1  1 1,3 
Miconazol eardrops2 1 1,3 
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Chapter 7.1  
 
Immediate contact reaction to 2-hydroxyethyl methacrylate? 
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Abstract 
A 24 years old female patient experienced immediate contact symptoms on two 
different visits at her dentist's, each time after the application of the bonding agent 
Clearfil Photobond Catalyst Liquid. We performed patch tests with the materials used 
by the dentist and the acrylates series for a 20 minutes' and 40 minutes' duration. We 
also performed a scratch test with Clearfil Photobond Catalyst Liquid 2.0% PET and  
2-hydroxyethyl methacrylate 1,0% PET and applied them for 20 minutes. 
After 20 minutes patch test duration there was a weak 1+ reaction to Clearfil 
Photobond Catalyst Liquid 2.0% PET. After 9 hours a 1+ reaction occurred to 2-
hydroxyethyl methacrylate 1,0% PET, that persisted for 14 days. About 8 hours after 
the scratch test an itching, erythematous reaction appeared on the scratched sites 
where Clearfil Photobond Catalyst Liquid 2.0% PET and the 2-hydroxyethyl 
methacrylate 1,0% PET had been applied for 20 minutes. Both reactions disappeared 
again after another 12 hours. 
Can the patient's symptoms be described as an immediate contact reaction? The test 
reactions cannot support this theory. Is this “a very late type I reaction” or should we 
see it as an allergic reaction in between a type I and type IV allergy? 
 
Keywords 
acrylates, 2-hydroxyethyl methacrylate (2-HEMA), immediate contact reaction, patch 
testing, scratch test
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Introduction 
Acrylates are commonly used in dentistry for restorations and protheses. They are 
also used in preparing artificial fingernails. Dentin-bonding acrylates are strong 
sensitizers and even a single exposure may sensitize (1). 
Occupational contact allergies to dental acrylates are increasing (2). Among dental 
personnel in the county of Värmland, Sweden, the prevalence of allergy to acrylates, 
verified by patch testing, was 3% (3). A clinical picture of long-standing eczema, 
especially on the fingertips (pulpitis) with hyperkeratotic, scaling skin with painful 
fissures, reduced sensation and in some cases also paresthesias, is typical (4). 
2-hydroxyethyl methacrylate (2-HEMA) is one of the most often found positive in 
patch testing acrylates (1,5,6). 
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Case reports 
A 24 years old female patient was referred to our department of Dermatology by her 
dentist. A first time in 1996 and a second time in November 1999, during her dental 
visit, she encountered problems of flushing of the face and presternal region, 
generalized tremor, perioral sensations and itching of both hands. The dentist treated 
these presyncopal symptoms with Adrenalin and Prednison on which they gradually 
disappeared. No oral or perioral lesions or dermatitis was observed. 
The patient’s dermatological and general medical history was clear and she did not 
take any medication. 
Both visits, the dentist treated her with composite materials and a dentin-bonding 
agent. The dentist confirmed that the reaction appeared after application of the 
bonding agent. On other (control) visits she never encountered any problems at the 
dentist's. 
In 1997 she had been patch tested with the standard series, dental series and 
materials used by her dentist. No relevant reactions were observed at that time. 
Percutaneous tests showed positive reactions to several inhalation allergens, thus an 
atopic constitution. 
After the second episode of symptoms, in November 1999, she was referred to our 
center for further investigation. Because no dermatitis had been observed and 
because the symptoms are closer related to a type I than to a type IV allergic 
reaction, we decided to perform 20 minutes patch tests with the materials delivered 
by her dentist. Because there was not a clear positive reaction after the 20 minutes, 
we repeated the patch test for 40 minutes. The different materials tested are shown 
in Table 1. We also performed a prick test with 1000, 10.000 and 100.000 BU/ml 
Latex and the local anesthetic Septanest. 
The patch tests were performed using van der Bend Patch Test Chambers, affixed 
with Fixomull Stretch tape. The test substances were removed after 20 minutes the 
first time and after 40 minutes the second time. The test results were read according 
to international guidelines immediately after the 20 minutes and after the 40 minutes. 
The patient was asked to come back to the department if a late reaction should 
occur. The same tests were also performed in 5 healthy control subjects. 
After 20 minutes patch test duration there was a weak 1+ reaction to Clearfil 
Photobond Catalyst Liquid 2.0% PET. After 40 minutes patch test duration we 
observed a 1+ reaction to Hytac Aplitip Compromer Bonding in pure test 
  109 
concentration and to Clearfil Photobond Catalyst Liquid 2.0% PET. After 9 hours the 
patient came back to the department because of a 1+ reaction that occurred to 2-
hydroxyethyl methacrylate 1,0% PET. This local reaction persisted for 14 days. The 
prick tests with Latex and the local anesthetic Septanest remained negative. The 
tests in the control subjects were all negative. 
Because it still wasn’t clear to us whether an immediate type of allergic reaction was 
involved, we performed scratch tests one month later. The skin was scratched on 
four different sites on the volar surfaces of the forearms. Then we applied the Clearfil 
Photobond Catalyst Liquid 2.0% PET and the 2-hydroxyethyl methacrylate 1,0% PET 
respectively for 20 minutes. The other two scratched sites were used as positive 
(Histamin) and negative (Petrolatum) controls. After 20 minutes the substances were 
removed and the test sites were read. All sites were negative except for the positive 
control. About 8 hours later an itching, erythematous reaction appeared on the 
scratched sites where Clearfil Photobond Catalyst Liquid 2.0% PET and the 2-
hydroxyethyl methacrylate 1,0% PET had been applied for 20 minutes. Both 
reactions disappeared again after another 12 hours. 
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Discussion 
Clearfill Photo Bond (Kuraray Co., LTD.) is a dual curing dentin and enamel bonding 
agent developed for use with composite light-curing restorative materials. The 
components of the catalyst liquid are Bisphenol A diglycidylmethacrylate, 10-
methacryloyloxydecil dihydrogen phosphate, 2-hydroxyethyl methacrylate, 
hydrophobic dimethacrylate, benzoyl peroxide and dI-camphorquinone. The universal 
liquid to use with it contains N,N’-diethanol-p-toluidine, sodium benzen sulfinate and 
ethyl alcohol. 
We assume the 1+ reactions to Clearfil Photobond Catalyst Liquid after 20 minutes 
and to one of its constituents 2-hydroxyethyl methacrylate after 9 hours are relevant, 
but it remains unclear what the underlying mechanism is. The patient’s symptoms are 
likely to be caused by a type I allergic reaction, but the test reactions cannot support 
this theory. At the other hand a type IV allergic reaction would likely cause a different 
clinical picture with gingivitis, stomatitis, and perioral dermatitis and later reactions 
during patch testing, as described by Kanerva (7). 
Also, very late patch test reactions to acrylates have been described. Fowler has 
observed a patch test reaction to acrylates after 5 weeks in a dental worker with 
eyelid and hand dermatitis (8). 
In literature there have been reports of immediate hypersensitivity and/or bronchial 
asthma on acrylates or acrylic acid (1,9), but the exact mechanism remains 
mysterious.  
It also is difficult to determine the best test method in a case like this. Kanerva states 
that dental acrylics should never be patch tested "as is". He also discourages the 
practice of use tests, open tests, or repeated open patch tests with undiluted dental 
acrylics because of the risk of active sensitization from single exposure (10). 
It is difficult to interpret the patient's symptoms and the patch and scratch test 
reactions in this case. Can the patient's symptoms be described as an immediate 
contact reaction? Can we interpret the reaction after 9 hours to a patch test duration 
of 40 minutes as “a very late type I reaction” or should we see it as an allergic 
reaction in between a type I and type IV allergy? The same question goes for the 
reactions on the scratch tests, that appeared after 8 hours and disappeared again 
another 12 hours later. 
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Table 1:  
Materials used by the patient’s dentist and patch tested for 40 minutes. 
 
Benzoyl peroxyde 1.0% PET 
N,N’-dimethyl-P-toluidin 2.0% PET 
2-hydroxyethyl methacrylate 1.0% PET 
BIS-EMA 1.0% PET 
BIS-GMA 2.0% PET 
BIS-MA 2.0% PET 
Bisphenol A 1.0% PET 
Methyl methacrylate 2.0% PET 
Clearfil Photobond Catalyst Liquid 2.0% PET 
Clearfil Photobond Universal Liquid 2.0% PET 
Epoxy resin 1.0% PET 
Hydroquinon 1.0% PET 
Ethyleleglycol dimethacrylate (EGDMA) 2.0% PET 
Primer and Bond Dental Adhesive 2.0% PET 
Primer and Bond Dental Adhesive Pure 
Hytac Aplitip Compromer Bonding 2.0% PET 
Hytac Aplitip Compromer Bonding Pure 
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Abstract 
We report on three tracheostomized patients with dermatitis around the stoma, which 
used a cleansing tissue to remove glue from adhesive materials, used to protect their 
tracheostoma. In all three of them, this cleansing tissue caused an acute dermatitis. 
We performed patch tests with the tissues as is, causing severe reactions in all three 
patients as well as in 5 healthy control subjects. In 20 healthy subjects a 5% and a 
10% concentration of the extract was patch tested, causing + reactions to the 10% 
concentration, but not to the 5% concentration. 
We conclude that cleansing tissues to remove glue can cause severe irritant 
reactions, especially in susceptible skin, in casu around tracheostomata. 
 
Keywords 
irritant contact dermatitis, tracheostomized patients, tracheostoma, patch testing, 
solvents 
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Case reports 
A 59-year-old and a 56-year-old female and a 60-year-old male, tracheostomized 
patients, were referred to our test clinic because of dermatitis around the 
tracheostoma. The complaints of severe itching existed for several months. On 
clinical examination, we observed a diffuse erythema with scaling and crusting. The 
complaints and clinical picture were similar in all three patients. They were subjected 
to patch testing with the European standard series, their own topical materials 
(several cleansing tissues and adhesive materials used with the tracheostoma) and 
additional series if appropriate. The tests were performed using van der Bend Patch 
Test Chambers, affixed with Fixomull Stretch tape. The test substances were 
removed after 48 hours and the test results were read according to international 
guidelines at 48 and 72 hours. 
The three patients reacted to the cleansing tissues, which they used to remove glue 
from the skin around the tracheostoma. We observed a + reaction after 48 and 72 
hours in the first patient, a ++ reaction after 48 hours and a +++ reaction after 72 
hours in the second patient and a +++ reaction after 48 and 72 hours in the third. 
In the last patient a + reaction to methyldibromoglutaronitrile (0,3% pet.) was also 
observed after 72 hours. 
The dermatitis cleared when the patients stopped using the specific cleansing 
tissues. 
We performed patch test with the pure tissues and with a 10% concentration of the 
extract in alcohol in 5 healthy subjects. Two of them developed a contact urticaria 
reaction at the pure tissue test site with severe itching and erythema. This is likely to 
be due to the isopropyl alcohol in the ingredient mix of the tissue (1). In the other 3 
the pure tissue had also to be removed because of burning sensations and severe 
erythema after several hours. The 10% concentration of the extract caused an itching 
reaction with erythema after several hours in the two healthy subjects that 
experienced the contact urticaria with the pure tissue. In the other 3 subjects there 
was no reaction to the 10% concentration after 72 hours. 
In addition, we tested 20 other healthy subjects with a 5% and a 10% concentration 
of the extract. In 10 (50,0%) of them there was a + reaction to the 10% concentration 
after 72 hours. 
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Discussion 
We found one case report on dermatitis in tracheostomized patients. Mitxelena et al. 
reports from a contact dermatitis in a patient due to a rubber disc (2).  
After testing the healthy subjects we conclude that the cleansing tissue that these 3 
patients used was irritant and the likely cause of the dermatitis around their 
tracheostoma. 
The ingredients of these tissues are isopropyl alcohol, benzyl alcohol, fragrances, 
isoparaffin, dipropylene glycol methyl ether and Aloëvera extract. 
The tracheostomized patients could not be retested with the 5% or the 10% 
concentration of the extract or with the separate ingredients because of their poor 
general condition. 
Patch testing cleansing tissues as is can cause serious irritant reactions. These 
materials, containing several solvents, are to be used on a fragile and susceptible 
skin, in casu around tracheostomata. We recommend testing the cleansing material 
in an appropriate dilution of the extract depending on the ingredients, in our case, 
with the 5% concentration of the extract in alcohol.  
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Case Report 
A 25-year-old woman presented with a 2-year history of dermatitis in the axillary and 
presternal region. She had had atopic dermatitis until puberty. She worked in a cheese 
factory where she wore latex gloves. 2 years before she had been patch tested, with 
only one reading, and remained negative. She mentioned problems with perfumes when 
applied directly onto the skin. She treated the dermatitis with dermatocorticosteroids.
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We re-performed patch testing with the Belgian standard series, our cosmetics series 
and the patient’s own products (perfumes and deodorants). Readings were done at D2 
and D4. Fragrance mix was + at both readings. There was a + reaction to farnesol at D2, 
but this became ?+ by D4. 6 out of the 8 own products tested showed a + reaction at D4: 
2 deodorants (Secret Nature Fresh and Secret Exotic Fresh (Procter&Gamble, 
Weybridge, Surrey, UK)), 3 perfumes (Paco Rabanne, Deep Red Hugo Boss and White 
Jeans Versace) and 1 perfumed moisturizing milk (Hydramilk Lancôme).  
We also patch tested with the different ingredients of 2 of the responsible dry stick 
deodorants (Secret Nature Fresh and Secret Exotic Fresh (Procter&Gamble, Weybridge, 
Surrey, UK)), which were supplied by the manufacturer. The 3 out of the 11 ingredients 
that were + at D2 were 12-hydroxystearic acid (2% pet.), fragrance Montana (10% pet.) 
and fragrance Confidence Plus (10% pet.). Only the latter 2 remained + at D4. 
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Discussion 
Chemical analysis by Johansen et al revealed that deodorants contain on average 3 
fragrance-mix constituents (1). Gallego et al described an irritant contact dermatitis of 
the axillae from an alum-containing deodorant (2). Lyral (3), as well as farnesol (4), can 
also be allergens found in deodorants. 
GC-MS analysis combined with structure-activity relationship analysis may be valuable 
in exploring allergy to deodorants (5). 
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In chapter 1 the epicutaneous patch testing is discussed. The procedure is regarded 
as the best method to diagnose allergic contact dermatitis. Patch tests can be used 
to confirm a suspected allergic contact dermatitis either to recommend avoidance of 
particular products/chemicals and/or to recommend alternative products in a 
particular patient. A careful history taking and attention for the clinical picture are key 
actions to facilitate the interpretation of the clinical relevance of the epicutaneous 
patch test results. A patch test should cause as few adverse reactions as possible. 
Many adverse reactions have been described, which can be minimized by skilful 
testing. The overall risk-benefit equation of patch testing is considered to be in favour 
of the benefit. 
We conclude that epicutaneous patch testing is a useful procedure if it is well 
performed and if it is performed on the right indication. Problems concerning the 
validity, accuracy, relevance and side effects of the procedure remain. 
 
In chapter 2 a potential side effect of patch testing is described. Para-
phenylenediamine (PPD) and para-aminoazobenzene are strong sensitizers. By the 
patch test procedure, the patient may be sensitized to these agents (active 
sensitization), especially if tested simultaneously. Combined testing of para-
compounds may increase the risk of active sensitization and should therefore be 
discouraged. 
 
Evidence based medicine (EBM) is defined as the integration of the best research 
evidence with clinical expertise and patient values. EBM applied to diagnostics and 
screening is referred to as evidence based diagnosis (EBD). On the basis of EBD, as 
described in chapter 3, we can conclude that patch testing is only then cost-effective 
if patients are selected with a clear clinical suspicion of contact allergy and only if 
patients are tested with chemicals relevant to the problem (high pre-test probability). 
Results of random patch testing (low pre-test probability) should be interpreted with 
great care, because they are rarely relevant. 
 
Fragrances are an important cause of allergic contact dermatitis. We assume that the 
fragrance mix (FM) alone, used as a tool in the European standard series to 
diagnose fragrance sensitization, detects 70-80% of the fragrance allergic patients. 
The FM has an irritant potential. This means that weakly positive reactions will have a 
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higher chance to be irrelevant than strong reactions. In chapter 4 we report on the 
relevance of patch test reactions of different strength to the FM and on predictive 
factors to this relevance in order to help the clinician to judge positive patch test 
reactions more accurately. Our findings show that if any doubt exists on the 
relevance of a weakly positive reaction to the FM, re-testing the FM and its 
ingredients adds significantly to the accuracy of the diagnostic procedure. 
 
In chapter 5 we present our patch test findings with dermatocorticosteroids during the 
period 1995-1999. We retrospectively studied the percentage of doubtful and positive 
reactions to each allergen in our corticosteroid series and assessed the relevance of 
these reactions. To assess reproducibility, we retested 15 patients with doubtful or 
positive reactions. An overall reproducibility of 47.2% was obtained, 100.0 % of the 
non-reproducible patch test reactions were not relevant. Definite relevance was much 
higher in the reproducible positive reactions than in the reproducible doubtful 
reactions: 100.0% and 18.2% respectively. Tixocortol pivalate and budesonide 
proved to be important markers for dermatocorticosteroid contact allergy. 
In chapter 6 we report on the patch test results of 79 patients suffering from chronic 
otitis externa with the European standard series, a standard series of topical 
medication, own topical materials and additional series if appropriate. 35 Patients 
(44.3%) showed positive reactions. 22 Patients (27.8%) reacted to a topical aural 
preparation or its ingredients. Nine (11.4%) has used these topical drugs in the outer 
ear in the past, but not during the last 4 months. Four (5.1%) had never used topical 
aural preparations. The relevance of positive patch test reactions to ingredients of 
topical ear medication should be defined carefully. A positive patch test can be 
relevant to an allergic contact reaction superimposed on a pre-existent skin disease. 
However, a substantial number of our patients with positive patch test results did not 
use topical aural preparations during the last 4 months before testing. In this group 
the test results are relevant to future treatment policy, but not to the dermatitis 
actually present. 
 
In chapter 7 case reports are presented indicating the importance of thorough 
knowledge of the validity (7.1 and 7.2), the accuracy (7.3) and relevance (7.1, 7.2 
and 7.3) of the patch test procedure. In chapter 7.1 we discuss a probably relevant 
intermediate reaction between a type I and type IV reactions on 2-hydroxyethyl 
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methacrylate 1.0% in a patient suffering from erythema, flushing and perioral lesions 
after treatment with a bonding agent. This report casts doubt on the validity of the 
positive patch test result in this patient. Does the positive patch test reaction to on 2-
hydroxyethyl methacrylate 1.0% indicate a type IV allergic reaction? In 7.2 we report 
on strong irritant skin reactions to cleansing tissue to remove glue from adhesive 
materials, used to protect the skin around tracheostomas. Patch tests with the 
material 'as is' caused severe reactions. These reactions, although very relevant, do 
not indicate contact allergy, but indicate skin irritancy. In 7.3 we present a patient with 
an allergy to a deodorant. Initially patch testing did not confirm a contact allergic 
reaction. Repeated testing showed reactions to fragrances present in her deodorants. 
This report shows that patch tests may be false negative, and that repeated testing, if 
the history taking is suggestive for contact allergy, adds to the accuracy of the patch 
test procedure. 
 
The main conclusions of this thesis are: 
1 Epicutaneous patch testing is the method of choice to diagnose allergic 
contact dermatitis. It is a cost-effective procedure if it is performed according to 
the guidelines and on the right indication. 
2 Epicutaneous patch testing is a bio-assay. It aims at reproducing contact 
dermatitis in order to find the causing chemical(s). A positive reaction, also if 
read according to the guidelines, does not necessarily indicate an allergic 
contact reaction, but may also be the result of non-immunological phenomena. 
A negative reaction does not exclude allergic contact dermatitis. 
3 Epicutaneous patch testing may cause active sensitization. In order to 
minimize this risk, chemicals with a strong sensitization potential should only 
be tested if the patient's history and clinical examination makes an allergic 
contact dermatitis due to the specific chemical likely.  
4 Simultaneous testing of the chemically related compounds with strong 
sensitization potential like e.g. paraphenylenediamine and para-
aminoazobenzene may increase the risk of active sensitization. 
5 At random patch testing (low pre-test probability) carries the risk of low 
relevance of positive patch test results. Problem oriented testing may increase 
the cost-effectiveness of the procedure. 
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6 Weak positive reactions do have a greater chance to be irrelevant than strong 
reactions. In case of the fragrance mix and dermatocorticosteroids re-testing 
adds significantly to the accuracy of the diagnostic procedure. 
7 The use of topical aural preparations, containing antimicrobial drugs and 
corticosteroids, in otitis externa carries a high risk of sensitization. The 
relevance of a positive patch test should be defined carefully, because an 
allergic contact reaction may be superimposed on a pre-existent skin disease 
or the sensitization may be the result of past exposure. 
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Future perspectives 
 
We patch test the patient to diagnose a contact allergy in the assumption that the 
patch test procedure is valid, accurate and safe. If we observe a contact allergy, we 
make an assessment to the relevance for past or present skin disease.  Using the 
principles of evidence-based diagnosis we demonstrated that this assumption is not 
always correct and that a positive patch test may not always be relevant. 
In this thesis we discuss issues related to the importance (accuracy), relevance and 
safety of the patch test.  
 
The importance is dependent on the sensitivity and specificity of a test. As we have 
indicated in chapter 3 sound data on the sensitivity and specificity of the patch test 
are not available.  
 
The sensitivity of a test is defined as the proportion of the tested people in the studied 
population with the target disorder with a positive test. The specificity is defined as 
the proportion of negatively tested people with a negative test. In order to know the 
sensitivity and the specificity of a patch test we have to confirm the test result of each 
particular test substance. For this purpose we need a (gold standard) reference test. 
An in-vitro test like the lymphocyte transformation test show good correlation 
between proliferating lymphocytes and skin test reactivity, but the specificity of the 
test is low (1-3). Thus, for assessment of the true sensitivity and specificity rates we 
need an accurate in-vitro test or set of tests, which makes confirmation of a positive 
or negative patch test possible. This test is not yet available and development of such 
a test may be advisable to pursue. 
 
Although, as stated in chapter 3, the concepts of sensitivity and specificity are 
needed to determine the importance of a test, the clinician is more interested to what 
extent a diagnostic test can help to make a diagnosis more or less likely. In other 
words, the clinician is interested in the proportion of individuals diagnosed by the 
used test instrument (like patch testing), which is actually sensitised. This proportion 
is called positive predictive value and is a function of the sensitivity and specificity of 
the test, but also of the true prevalence of sensitisation in the tested population (4).  
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Consequently, we have to know the prevalence of contact allergies in order to be 
informed on the chance of a false positive reaction. The prevalence will, however, be 
dependent on the way cases are ascertained. How do the cases come to the 
attention of the investigator/physician? From what population does the patient come 
from and what is the prevalence of contact sensitisation in this specific group of 
persons (5)? The prevalence of contact sensitisation is studied in selected and to a 
lesser extent in unselected populations (5-7), but for many professions and 
populations at risk this information is not available. Moreover, changes in exposure 
e.g. by legislative measures, may also change the sensitisation risk in well-defined 
populations in time (8-10). Regional differences in prevalence have also been 
demonstrated (11). 
Future epidemiological studies may aim at filling in this gap in information on 
prevalence data. 
 
In this thesis we indicate that testing chemicals relevant to the problem oriented 
patch testing may be more cost-effective than random patch testing. However, in 
spite of thorough history taking it may be not possible and/or feasible to test all 
relevant substances. For example in case of suspected fragrance sensitivity it is not 
possible to test all the relevant fragrance ingredients, either because not all 
ingredients are known or not all ingredients can be obtained. In such situations the 
clinician can use mixes of test materials or marker substances instead. However, 
both the available mixes like e.g. the fragrance mix or a marker substance like e.g. 
tixocortol pivalate, do not always identify all sensitised individuals to fragrance 
materials or dermatocorticosteroids respectively. Future work may aim at increasing 
the sensitivity and specificity of indicator test substances (12,13). 
 
According to international (ICDRG) guidelines doubtful reactions (erythema) are read 
negatively and 1+ to 3+ reactions (weak, strong and extreme reactions respectively) 
positively. This partition is more or less arbitrary, while a doubtful reaction may be 
relevant and a weak reaction may be not relevant.  In this thesis we showed that the 
reproducibility and relevance of a test vary with the strength of a positive reaction 
(chapter 4). To a large extent the influence of the strength of the reaction on the odds 
of being relevant of a positively tested allergen is not known. Ideally this knowledge 
should become available to clinicians for all test substances in order to give evidence 
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based avoidance advices to positively tested patients. This will not be possible for all 
chemicals because sensitisation to a substance may be (extremely) rare and the list 
of contact allergens is very long. However, future studies may aim at obtaining 
information on the influence of the strength of a reaction on relevancy especially for 
those substances with a known marginal irritancy. 
 
As we have shown thorough history taking is essential for cost effective patch testing. 
Not all information needed for cost effective patch testing can be obtained in this way, 
because the ingredients of the products, which come into contact with the skin, are 
often not known to the patient. Time-consuming attempts to obtain this information 
are needed and tracing the exact composition of a product is not always possible. 
Therefore future legislation may aim at correct (legally bound) ingredient labelling, not 
only of cosmetics and body care products (14), but also of other products which may 
come into contact with the skin either of not accidentally. This ingredient labelling 
may not only help us to patch test the right chemicals, but can also help the patient 
with a proven contact allergy to avoid skin contact to products, which contain the 
specific allergen(s).  
  
Patch testing is relatively safe, although it may give rise to side effects. In chapter 2 
we pointed out at the possibility of active sensitisation, i.e. sensitisation by the patch 
test procedure. Especially if chemically related (strong sensitising) substances are 
tested simultaneously, this risk may become clinically relevant. Future studies may 
aim at accurate risk assessment of active sensitisation by patch testing, especially for 
(combinations of) strong sensitisers. Then a calculated risk can be taken either to 
include the particular strong sensitiser in standard test series or to test the substance 
only on strong clinical indication (this thesis, 15). 
In conclusion, we have shown in this thesis that epicutaneous patch testing is 
rewarding if both candidates for the test and test substances are selected on basis of 
thorough history taking and good clinical examination. Unnecessary side effects, 
false positive tests and missed allergies can be avoided in this way. If patients test 
positively to one or more substances, the relevance of these findings should be 
determined carefully. Moreover tested patients will benefit significantly by information 
on the composition of (complex) materials (ingredient labelling) and  testing will 
benefit from better epidemiological data.     
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In hoofdstuk 1 wordt de epicutane allergietest (plaktest) besproken. De procedure 
wordt beschouwd als de beste methode om een contactallergie te diagnostiseren. 
Het doel is een eventueel advies tot het vermijden van specifiek (oorzakelijke) 
producten of chemicaliën en/of het advies om alternatieve producten, die het 
oorzakelijk allergeen niet bevatten, te gebruiken. Een nauwkeurige anamnese en 
bestudering van het klinisch beeld zijn de belangrijkste factoren bij de interpretatie 
van de klinische relevantie van de testresultaten. Vele bijwerkingen van de plaktest 
zijn beschreven. Deze kunnen bij een juist gebruik en een juiste toepassing van de 
test tot een minimum worden beperkt.  De kostenbaten analyse van de plaktest wordt 
dan ook als positief beschouwd. Problemen betreffende de validiteit, nauwkeurigheid, 
relevantie en bijwerkingen van de procedure blijven echter bestaan. 
 
In hoofdstuk 2 wordt een bijwerking van de plaktest beschreven. 
Paraphenyleendiamine en para-aminoazobenzeen zijn sterke sensibilisatoren. Door 
de allergietest kan de patiënt voor deze stoffen overgevoelig worden, met name 
indien deze stoffen tegelijkertijd worden getest (actieve sensibilisatie). Gecombineerd 
testen van paraverbindingen verhogen de kans op actieve sensibilisatie en zouden 
daarom zo min mogelijk moeten worden uitgevoerd.  
 
'Evidence based' geneeskunde wordt gedefinieerd als het integreren van de 
beschikbare wetenschappelijke informatie met de klinische ervaring van de arts en 
de specifieke wensen van de patiënt. 'Evidence based' geneeskunde kan ook worden 
toegepast bij de keuzes die worden gemaakt bij het verrichten van diagnostiek. In dit 
geval kan men spreken van 'evidence based' diagnosestelling. In hoofdstuk 3 wordt 
beschreven hoe we op basis van principes die worden gehanteerd bij 'evidence 
based' diagnosestelling kunnen concluderen dat de epicutane allergietest 
kosteneffectief is indien de patiëntenselectie op basis van een duidelijke klinische 
verdenking op een contactallergie plaatsvindt. Ook dient er te worden getest met 
chemische stoffen relevant ten aanzien van het klinisch probleem (hoge pretest 
waarschijnlijkheid). Resultaten van willekeurig testen (lage pretest waarschijnlijkheid) 
dienen met grote zorgvuldigheid te worden beschouwd omdat zij zelden relevant zijn. 
 
Parfumgrondstoffen vormen een belangrijke oorzaak van allergisch contact eczeem. 
We veronderstellen dat de parfummix alleen, zoals gebruikt in de Europese 
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standaardserie om een parfumallergie vast te stellen, 70-80% van de patiënten met 
een parfumallergie opspoort. De parfummix heeft echter irritatieve eigenschappen. 
Dit betekent dat zwak positieve reacties, die irritatief van aard kunnen zijn, 
zorgvuldiger dienen te worden bestudeerd op relevantie. In hoofdstuk 4 wordt 
gerapporteerd over de relevantie van positieve plaktesten op de parfummix van 
verschillende sterkte en op voorspellende factoren van invloed op deze relevantie 
met als doel de arts te helpen om de positieve resultaten beter te kunnen 
beoordelen. Onze resultaten laten zien dat, indien er twijfel bestaat over de relevantie 
van zwakpositieve reacties op de parfummix, het hertesten van de mix en van de 
individuele ingrediënten een significante bijdrage levert aan de nauwkeurigheid van 
de epicutane allergietest. 
 
In hoofdstuk 5 presenteren we de resultaten van plaktesten met 
dermatocorticosteroïden, die werden verricht in de periode van 1995-1999. 
Retrospectief bestudeerden wij het percentage van zwak positieve en positieve 
reacties op de bestanddelen van de corticosteroïdserie en bestudeerden we de 
relevantie van deze reacties. Om de reproduceerbaarheid te kunnen bepalen werden 
15 patiënten met twijfelachtige of positieve reacties opnieuw getest. Een 
reproduceerbaarheid van 47,2% werd gevonden. Van de niet reproduceerbare 
resultaten was 100% niet relevant. De relevantie was veel hoger in de 
gereproduceerde positieve reacties in vergelijking tot zwak positieve (twijfelachtige) 
reacties die konden worden gereproduceerd (100% versus 18,2% respectievelijk). 
Tixocortol pivalaat en budesonide bleken belangrijke indicatoren te zijn voor een 
contactallergie voor dermatocorticosteroïden.  
 
In hoofdstuk 6 beschrijven wij de resultaten van plaktesten met de Europese 
standaardserie, een standaardserie bestaande uit topische medicatie, eigen topische 
materialen en eventueel aanvullende series bij 79 patiënten die leden aan een 
chronische otitis externa. Van de patiënten toonden 35 personen (44,3%) positieve 
reacties, 22 patiënten (27,8%) reageerden op een lokaal in het oor toe te passen 
preparaat of ingrediënten daarvan, negen (11,4%) patiënten gebruikten de topische 
medicatie in de uitwendige gehoorgang in het verleden, maar niet gedurende de 
laatste 4 maanden voorafgaand aan het bezoek aan de polikliniek. Vier patiënten 
(5,1%) hadden nooit oormedicatie gebruikt.  
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We concluderen dat een een positive plaktest slechts in een minderheid van de 
gevallen relevant is met betrekking tot een otitis externa. De contactallergie kan 
daarbij gesuperponeerd zijn op een reeds aanwezige dermatose.  
Echter een aanzienlijk deel van de patiënten met positieve plaktesten hadden geen 
oormedicatie gebruikt gedurende de laatste vier maanden voor het testen. In deze 
groep waren de resultaten niet relevant voor de huidige dermatitis van de uitwendige 
gehoorgang. De betreffende contactallergenen dienen wel te worden vermeden en 
derhalve zijn de resultaten van de test wel relevant voor toekomstige behandeling. 
 
In hoofdstuk 7 worden casuïstieken beschreven die het belang van een grondige 
kennis van de validiteit (7.1 en 7.2), de betrouwbaarheid (7.3) en de relevantie (7.1, 
7.2 en 7.3) van de epicutane allergie test onderschrijven. In hoofdstuk 7.1 wordt een 
waarschijnlijk relevante intermediaire reactie beschreven tussen een type I en een 
type IV reactie op 2 hydroxyethyl methacrylaat 1% bij een patiënt die een rood 
gezicht kreeg en afwijkingen rond de mond na een tandheelkundige behandeling. De 
dynamiek van de reactie roept twijfel op aan de validiteit van de test bij deze patiënt. 
Geeft de positieve plaktest op 2 hydroxyethyl methacrylaat een type IV allergische 
reactie aan? In 7.2 rapporteren wij over sterk irritatieve huidreacties op 
schoonmaakdoekjes die gebruikt worden om lijm te verwijderen van adhesieve 
materialen die zijn aangebracht om de huid rond een tracheostoma te beschermen. 
Het materiaal werd zonder bewerking getest en veroorzaakte ernstige reacties. Deze 
reacties, hoewel relevant voor de klachten, zijn irritatief van aard en duiden niet op 
een allergische contactreactie. In 7.3 presenteren wij een patiënt met een allergie 
voor een deodorant. In eerst instantie kon allergisch contactonderzoek de klinische 
verdenking op een allergie niet bevestigen. Herhaalde testen toonden positieve 
reacties op parfumgrondstoffen, die in haar deodorant aanwezig waren. De 
ziektegeschiedenis toont aan dat een plaktest fout negatief kan zijn. Een herhaalde 
test kan daarom bijdragen aan de nauwkeurigheid van de plaktest, met name indien 
de anamnese en het klinisch beeld suggestief is voor een contactallergie. 
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De belangrijkste conclusies in dit proefschrift zijn: 
1. Epicutaan allergologisch onderzoek is de methode van eerste keuze bij het 
diagnostiseren van een allergisch contacteczeem. De procedure is 
kosteneffectief, indien het wordt uitgevoerd volgens de richtlijnen en op een juiste 
indicatie. 
2. Epicutaan allergologisch onderzoek is een bioassay. De test poogt een 
contacteczeem te reproduceren met als doel het vinden van de oorzakelijke 
chemische verbinding(en). Een positieve reactie, ook indien deze wordt afgelezen 
volgens de richtlijnen, verwijst niet noodzakelijkerwijs naar een allergische 
contactreactie, maar kan ook het resultaat zijn van een non-immunologisch 
fenomeen. Een negatieve reactie sluit een allergisch contacteczeem niet uit. 
3. Epicutaan allergologisch onderzoek heeft het risico van actieve sensibilisatie. Dit 
risico kan worden beperkt door stoffen met een sterk sensibiliserend vermogen 
alleen te testen indien de voorgeschiedenis van de patiënt en het klinisch beeld 
een allergisch contacteczeem voor de specifieke chemische verbinding 
waarschijnlijk maakt.  
4. Tegelijkertijd testen van chemisch verwante stoffen met een sterk vermogen tot 
sensibiliseren, zoals b.v. paraphenyleendiamine en para-aminoazobenzeen 
kunnen de kans op actieve sensibilisatie doen toenemen. 
5. Het willekeurig doen van plaktesten (lage pretest waarschijnlijkheid) brengt het 
risico met zich mee van lage relevantie van positieve testresultaten. Het probleem 
georiënteerd testen kan de kosteneffectiviteit van de procedure doen toenemen. 
6. Zwakpositieve reacties hebben een grote kans om niet relevant te zijn dan sterke 
reacties. In het geval van de parfummix en van dermatocorticosteroïden kan het 
hertesten significant bijdragen aan een verhoogde betrouwbaarheid van de 
diagnostische procedure.  
7. Het gebruik van externe therapeutica die antimicrobiële stoffen en 
corticosteroïden bevatten in de uitwendige gehoorgang veroorzaken in een hoog 
percentage sensibilisatie. De relevantie van de gevonden positieve plaktesten 
dienen echter nauwkeurig te worden geëvalueerd, omdat een allergische 
contactreactie gesuperponeerd kan zijn op een preëxistente huidziekte of omdat 
de sensibilisatie het resultaat kan zijn van blootstelling in het verleden. 
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Toekomstperspectieven 
 
Wij voeren plaktesten uit om een contactallergie bij de patiënt te diagnosticeren in de 
veronderstelling dat de plakproefprocedure een zekere validiteit heeft, accuraat is en 
veilig. Indien wij een contactallergie vaststellen, proberen wij de relevantie in te 
schatten in het kader van vroegere of op heden aanwezige huidziekte. Ons baserend 
op de principes van evidence-based diagnosis, toonden wij aan dat deze 
veronderstellingen niet steeds juist zijn en dat een positieve plaktest reactie niet altijd 
relevant is. 
In dit proefschrift bespreken wij zaken die gerelateerd zijn aan de accuraatheid, de 
relevantie en de veiligheid van het plaktesten. 
 
De accuraatheid hangt af van de gevoeligheid en de specificiteit van de test. Zoals 
we hebben aangegeven in hoofdstuk 3 zijn harde data over de gevoeligheid en 
sensitiviteit van de plakproeven niet voor handen. 
 
De gevoeligheid van een test wordt gedefinieerd als de proportie van de geteste 
personen in de populatie met de ziekte die een positieve test heeft. De specificiteit 
wordt gedefinieerd als de proportie gezonde personen in de populatie met een 
negatieve test. Om de gevoeligheid en de specificiteit van een plaktest te kennen, 
moeten wij het testresultaat van elke aparte testsubstantie kunnen bevestigen. 
Hiervoor hebben wij een referentietest, een gouden standaard, nodig. Een in-vitro 
test zoals de lymfocyt transformatie test toont een goede correlatie aan tussen 
prolifererende lymfocyten en de huid test reactiviteit, maar de specificiteit van die test 
is laag (1-3). Zodoende hebben wij een accurate in-vitro test of een set van 
verschillende tests nodig, die een bevestiging van een positieve of negatieve 
plakproef mogelijk maken. Dergelijke test is nog niet beschikbaar en de ontwikkeling 
hiervan is het zeker waard na te streven. 
Niettegenstaande, zoals in hoofdstuk 3 besproken, de concepten van sensitiviteit en 
specificiteit nodig zijn om het belang van een test te bepalen, is de clinicus meer 
geïnteresseerd in welke mate een diagnostische test kan helpen om een bepaalde 
diagnose meer of minder waarschijnlijk te maken. Met andere woorden, de clinicus is 
geïnteresseerd in de proportie gesensibiliseerde patiënten welke door het 
testinstrument (plakproeven) worden gediagnosticeerd. Deze proportie wordt de 
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positieve voorspellende waarde genoemd en is functie van de sensitiviteit en 
specificiteit van de test, maar eveneens van de echte prevalentie van sensibilisatie in 
de geteste populatie (4). 
Bijgevolg moeten wij de prevalenties van contactallergie kennen om geïnformeerd te 
zijn over de kans op een fout positieve reactie. De prevalentie is echter afhankelijk 
van de manier waarop de gevallen worden nagegaan. Hoe komen de gevallen tot de 
aandacht van de onderzoeker/clinicus? Uit welke populatie komt de patiënt en wat is 
de prevalentie van contactsensibilisatie in deze specifieke groep (5)? De prevalentie 
van contactsensibilisatie wordt bestudeerd in geselecteerde, en in mindere mate in 
niet-geselecteerde populaties (5-7), maar voor vele beroepen en risicopopulaties is 
deze informatie echter niet beschikbaar. Meer nog, verandering in blootstelling, b.v. 
opgelegd door wetgeving, kan eveneens het risico op sensibilisatie in 
goedgedefinieerde populaties veranderen in de loop van de tijd (9-11). Er werden 
eveneens regionale verschillen in prevalentie aangetoond (12). 
Toekomstige epidemiologische studies zouden zich moeten richten op het bekomen 
van deze informatie betreffende prevalentie. 
In deze thesis geven wij aan dat producten testen, die relevant zijn voor het 
probleem/ziekte (georiënteerd plaktesten) meer kostenefficiënt is dan willekeurig 
plaktesten. Echter, niettegenstaande zorgvuldige anamnese, kan het onmogelijk 
en/of ondoenbaar zijn om alle relevante stoffen te testen. Bijvoorbeeld in het geval 
van verdenking op gevoeligheid voor parfumgrondstoffen is het onmogelijk om alle 
relevante ingrediënten te testen, ofwel omdat niet alle ingrediënten gekend zijn of 
omdat niet alle ingrediënten kunnen worden verkregen. In dergelijke situaties kan de 
clinicus mixen gebruiken van verschillende teststoffen of ‘marker’-substanties. 
Echter, zowel de beschikbare mixen, b.v. de parfummix, en de ‘marker’-substantie, 
b.v. tixocortol pivalaat, identificeren niet steeds alle gesensibiliseerde personen met 
gevoeligheid voor parfums of dermatocorticosteroïden respectievelijk. Toekomstig 
werk zou zich kunnen richten op het verhogen van de sensitiviteit en specificiteit van 
deze test substanties (13,14). 
 
Volgens de internationale (ICDRG) richtlijnen worden twijfelachtige reacties 
(erytheem) gelezen als negatief en 1+ tot 3+ reacties (zwak, sterk en zeer sterke 
reacties respectievelijk) als positief. Deze indeling is min of meer arbitrair, vermits 
een twijfelachtige reactie relevant kan zijn en een zwakke reactie niet relevant. In dit 
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proefschrift toonden wij aan dat de reproduceerbaarheid en de relevantie van een 
test varieert met de sterkte van een positieve reactie (hoofdstuk 4). De invloed van 
de sterkte van de reactie op de kansen om relevant te zijn van een positief getest 
allergeen is in grote mate ongekend. Het zou ideaal zijn, mocht deze kennis 
beschikbaar zijn voor de clinici en dit voor alle testsubstanties om aan positief 
geteste patiënten ‘evidence-based’ advies te kunnen geven omtrent het vermijden 
van bepaalde stoffen. Dit zal echter nooit mogelijk zijn voor alle chemicaliën gezien 
sensibilisatie voor een bepaalde substantie (extreem) zeldzaam kan zijn en gezien 
de lijst van contactallergenen zeer lang is. Toch zouden toekomstige studies tot doel 
kunnen hebben om informatie te bekomen over de invloed van de sterkte van een 
reactie op relevantie en dat in het bijzonder voor de stoffen met een gekend irritatief 
karakter. 
 
Zoals wij hebben aangetoond is zorgvuldige anamnese essentieel voor 
kostenefficiënt plaktesten. Niet alle informatie kan echter op deze manier worden 
verkregen omdat de ingrediënten van de producten, die soms met de huid in contact 
komen, niet altijd door de patiënt gekend zijn. Tijdrovende pogingen om deze 
informatie te bekomen zijn nodig en de juiste samenstelling van een product 
opsporen is niet altijd mogelijk. Hiertoe zou de wetgeving in de toekomst correcte 
vermelding moeten opleggen van de ingrediënten, niet alleen van cosmetica en 
lichaamverzorgingsproducten (11), maar ook van andere stoffen die mogelijks, al of 
niet per ongeluk, in contact kunnen komen met de huid. Deze vermelding van 
ingrediënten kan ons niet alleen helpen de juiste substanties te plaktesten, maar kan 
ook de patiënt met een bewezen contactallergie helpen de correcte producten te 
vermijden, die de specifieke allergenen bevatten. 
 
Niettegenstaande het feit dat het verrichten van plaktesten relatief veilig is, kan het 
toch aanleiding geven tot bijwerkingen. In hoofdstuk 2 wezen wij op de mogelijkheid 
tot actieve sensibilisatie ten gevolge het plaktesten. Voornamelijk wanneer chemisch 
gerelateerde (sterk sensibiliserende) substanties simultaan worden getest, kan dit 
risico klinisch relevant worden. Verdere studies moeten accuraat risico-onderzoek tot 
actieve sensibilisatie uitmaken, voornamelijk voor (combinaties van) sterk 
sensibiliserende substanties. Dan zou een berekend risico kunnen worden genomen 
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om al of niet een bepaalde sterk sensibiliserende substantie in de standaard serie op 
te nemen of om deze stof enkel te testen bij sterke klinische indicatie (15,16). 
In dit proefschrift hebben we laten zien dat het uitvoeren van een plaktest de patiënt 
ten goede komt, mits er een goede patiëntenselectie plaatsvindt en de juiste 
materialen worden getest. Dit dient te gebeuren op basis van een nauwkeurige 
anamnese en een adequaat lichamelijk onderzoek. Onnodige bijwerkingen, fout 
positieve uitslagen en gemiste contactallergieën kunnen door een dergelijke aanpak 
worden voorkomen. Indien er een of meerdere positieve uitslagen zijn, dienen deze 
nauwkeurig te worden getoetst op relevantie. Bovendien zullen de patiënten meer 
baat hebben bij informatie over hun allergieën, indien de samenstelling van de soms 
complexe materialen vermeld worden op de verpakking. De kosteneffectiviteit van 
het testen zal ook toenemen, indien meer informatie beschikbaar zou komen over de 
epidemiologie van contactallergieën.  
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